1
|
Proietti M, Romiti GF, Vitolo M, Harrison SL, Lane DA, Fauchier L, Marin F, Näbauer M, Potpara TS, Dan GA, Maggioni AP, Cesari M, Boriani G, Lip GYH, Ekmekçiu U, Paparisto V, Tase M, Gjergo H, Dragoti J, Goda A, Ciutea M, Ahadi N, el Husseini Z, Raepers M, Leroy J, Haushan P, Jourdan A, Lepiece C, Desteghe L, Vijgen J, Koopman P, Van Genechten G, Heidbuchel H, Boussy T, De Coninck M, Van Eeckhoutte H, Bouckaert N, Friart A, Boreux J, Arend C, Evrard P, Stefan L, Hoffer E, Herzet J, Massoz M, Celentano C, Sprynger M, Pierard L, Melon P, Van Hauwaert B, Kuppens C, Faes D, Van Lier D, Van Dorpe A, Gerardy A, Deceuninck O, Xhaet O, Dormal F, Ballant E, Blommaert D, Yakova D, Hristov M, Yncheva T, Stancheva N, Tisheva S, Tokmakova M, Nikolov F, Gencheva D, Shalganov T, Kunev B, Stoyanov M, Marchov D, Gelev V, Traykov V, Kisheva A, Tsvyatkov H, Shtereva R, Bakalska-Georgieva S, Slavcheva S, Yotov Y, Kubíčková M, Marni Joensen A, Gammelmark A, Hvilsted Rasmussen L, Dinesen P, Riahi S, Krogh Venø S, Sorensen B, Korsgaard A, Andersen K, Fragtrup Hellum C, Svenningsen A, Nyvad O, Wiggers P, May O, Aarup A, Graversen B, Jensen L, Andersen M, Svejgaard M, Vester S, Hansen S, Lynggaard V, Ciudad M, Vettus R, Muda P, Maestre A, Castaño S, Cheggour S, Poulard J, Mouquet V, Leparrée S, Bouet J, Taieb J, Doucy A, Duquenne H, Furber A, Dupuis J, Rautureau J, Font M, Damiano P, Lacrimini M, Abalea J, Boismal S, Menez T, Mansourati J, Range G, Gorka H, Laure C, Vassalière C, Elbaz N, Lellouche N, Djouadi K, Roubille F, Dietz D, Davy J, Granier M, Winum P, Leperchois-Jacquey C, Kassim H, Marijon E, Le Heuzey J, Fedida J, Maupain C, Himbert C, Gandjbakhch E, Hidden-Lucet F, Duthoit G, Badenco N, Chastre T, Waintraub X, Oudihat M, Lacoste J, Stephan C, Bader H, Delarche N, Giry L, Arnaud D, Lopez C, Boury F, Brunello I, Lefèvre M, Mingam R, Haissaguerre M, Le Bidan M, Pavin D, Le Moal V, Leclercq C, Piot O, Beitar T, Martel I, Schmid A, Sadki N, Romeyer-Bouchard C, Da Costa A, Arnault I, Boyer M, Piat C, Fauchier L, Lozance N, Nastevska S, Doneva A, Fortomaroska Milevska B, Sheshoski B, Petroska K, Taneska N, Bakrecheski N, Lazarovska K, Jovevska S, Ristovski V, Antovski A, Lazarova E, Kotlar I, Taleski J, Poposka L, Kedev S, Zlatanovik N, Jordanova S, Bajraktarova Proseva T, Doncovska S, Maisuradze D, Esakia A, Sagirashvili E, Lartsuliani K, Natelashvili N, Gumberidze N, Gvenetadze R, Etsadashvili K, Gotonelia N, Kuridze N, Papiashvili G, Menabde I, Glöggler S, Napp A, Lebherz C, Romero H, Schmitz K, Berger M, Zink M, Köster S, Sachse J, Vonderhagen E, Soiron G, Mischke K, Reith R, Schneider M, Rieker W, Boscher D, Taschareck A, Beer A, Oster D, Ritter O, Adamczewski J, Walter S, Frommhold A, Luckner E, Richter J, Schellner M, Landgraf S, Bartholome S, Naumann R, Schoeler J, Westermeier D, William F, Wilhelm K, Maerkl M, Oekinghaus R, Denart M, Kriete M, Tebbe U, Scheibner T, Gruber M, Gerlach A, Beckendorf C, Anneken L, Arnold M, Lengerer S, Bal Z, Uecker C, Förtsch H, Fechner S, Mages V, Martens E, Methe H, Schmidt T, Schaeffer B, Hoffmann B, Moser J, Heitmann K, Willems S, Willems S, Klaus C, Lange I, Durak M, Esen E, Mibach F, Mibach H, Utech A, Gabelmann M, Stumm R, Ländle V, Gartner C, Goerg C, Kaul N, Messer S, Burkhardt D, Sander C, Orthen R, Kaes S, Baumer A, Dodos F, Barth A, Schaeffer G, Gaertner J, Winkler J, Fahrig A, Aring J, Wenzel I, Steiner S, Kliesch A, Kratz E, Winter K, Schneider P, Haag A, Mutscher I, Bosch R, Taggeselle J, Meixner S, Schnabel A, Shamalla A, Hötz H, Korinth A, Rheinert C, Mehltretter G, Schön B, Schön N, Starflinger A, Englmann E, Baytok G, Laschinger T, Ritscher G, Gerth A, Dechering D, Eckardt L, Kuhlmann M, Proskynitopoulos N, Brunn J, Foth K, Axthelm C, Hohensee H, Eberhard K, Turbanisch S, Hassler N, Koestler A, Stenzel G, Kschiwan D, Schwefer M, Neiner S, Hettwer S, Haeussler-Schuchardt M, Degenhardt R, Sennhenn S, Steiner S, Brendel M, Stoehr A, Widjaja W, Loehndorf S, Logemann A, Hoskamp J, Grundt J, Block M, Ulrych R, Reithmeier A, Panagopoulos V, Martignani C, Bernucci D, Fantecchi E, Diemberger I, Ziacchi M, Biffi M, Cimaglia P, Frisoni J, Boriani G, Giannini I, Boni S, Fumagalli S, Pupo S, Di Chiara A, Mirone P, Fantecchi E, Boriani G, Pesce F, Zoccali C, Malavasi VL, Mussagaliyeva A, Ahyt B, Salihova Z, Koshum-Bayeva K, Kerimkulova A, Bairamukova A, Mirrakhimov E, Lurina B, Zuzans R, Jegere S, Mintale I, Kupics K, Jubele K, Erglis A, Kalejs O, Vanhear K, Burg M, Cachia M, Abela E, Warwicker S, Tabone T, Xuereb R, Asanovic D, Drakalovic D, Vukmirovic M, Pavlovic N, Music L, Bulatovic N, Boskovic A, Uiterwaal H, Bijsterveld N, De Groot J, Neefs J, van den Berg N, Piersma F, Wilde A, Hagens V, Van Es J, Van Opstal J, Van Rennes B, Verheij H, Breukers W, Tjeerdsma G, Nijmeijer R, Wegink D, Binnema R, Said S, Erküner Ö, Philippens S, van Doorn W, Crijns H, Szili-Torok T, Bhagwandien R, Janse P, Muskens A, van Eck M, Gevers R, van der Ven N, Duygun A, Rahel B, Meeder J, Vold A, Holst Hansen C, Engset I, Atar D, Dyduch-Fejklowicz B, Koba E, Cichocka M, Sokal A, Kubicius A, Pruchniewicz E, Kowalik-Sztylc A, Czapla W, Mróz I, Kozlowski M, Pawlowski T, Tendera M, Winiarska-Filipek A, Fidyk A, Slowikowski A, Haberka M, Lachor-Broda M, Biedron M, Gasior Z, Kołodziej M, Janion M, Gorczyca-Michta I, Wozakowska-Kaplon B, Stasiak M, Jakubowski P, Ciurus T, Drozdz J, Simiera M, Zajac P, Wcislo T, Zycinski P, Kasprzak J, Olejnik A, Harc-Dyl E, Miarka J, Pasieka M, Ziemińska-Łuć M, Bujak W, Śliwiński A, Grech A, Morka J, Petrykowska K, Prasał M, Hordyński G, Feusette P, Lipski P, Wester A, Streb W, Romanek J, Woźniak P, Chlebuś M, Szafarz P, Stanik W, Zakrzewski M, Kaźmierczak J, Przybylska A, Skorek E, Błaszczyk H, Stępień M, Szabowski S, Krysiak W, Szymańska M, Karasiński J, Blicharz J, Skura M, Hałas K, Michalczyk L, Orski Z, Krzyżanowski K, Skrobowski A, Zieliński L, Tomaszewska-Kiecana M, Dłużniewski M, Kiliszek M, Peller M, Budnik M, Balsam P, Opolski G, Tymińska A, Ozierański K, Wancerz A, Borowiec A, Majos E, Dabrowski R, Szwed H, Musialik-Lydka A, Leopold-Jadczyk A, Jedrzejczyk-Patej E, Koziel M, Lenarczyk R, Mazurek M, Kalarus Z, Krzemien-Wolska K, Starosta P, Nowalany-Kozielska E, Orzechowska A, Szpot M, Staszel M, Almeida S, Pereira H, Brandão Alves L, Miranda R, Ribeiro L, Costa F, Morgado F, Carmo P, Galvao Santos P, Bernardo R, Adragão P, Ferreira da Silva G, Peres M, Alves M, Leal M, Cordeiro A, Magalhães P, Fontes P, Leão S, Delgado A, Costa A, Marmelo B, Rodrigues B, Moreira D, Santos J, Santos L, Terchet A, Darabantiu D, Mercea S, Turcin Halka V, Pop Moldovan A, Gabor A, Doka B, Catanescu G, Rus H, Oboroceanu L, Bobescu E, Popescu R, Dan A, Buzea A, Daha I, Dan G, Neuhoff I, Baluta M, Ploesteanu R, Dumitrache N, Vintila M, Daraban A, Japie C, Badila E, Tewelde H, Hostiuc M, Frunza S, Tintea E, Bartos D, Ciobanu A, Popescu I, Toma N, Gherghinescu C, Cretu D, Patrascu N, Stoicescu C, Udroiu C, Bicescu G, Vintila V, Vinereanu D, Cinteza M, Rimbas R, Grecu M, Cozma A, Boros F, Ille M, Tica O, Tor R, Corina A, Jeewooth A, Maria B, Georgiana C, Natalia C, Alin D, Dinu-Andrei D, Livia M, Daniela R, Larisa R, Umaar S, Tamara T, Ioachim Popescu M, Nistor D, Sus I, Coborosanu O, Alina-Ramona N, Dan R, Petrescu L, Ionescu G, Popescu I, Vacarescu C, Goanta E, Mangea M, Ionac A, Mornos C, Cozma D, Pescariu S, Solodovnicova E, Soldatova I, Shutova J, Tjuleneva L, Zubova T, Uskov V, Obukhov D, Rusanova G, Soldatova I, Isakova N, Odinsova S, Arhipova T, Kazakevich E, Serdechnaya E, Zavyalova O, Novikova T, Riabaia I, Zhigalov S, Drozdova E, Luchkina I, Monogarova Y, Hegya D, Rodionova L, Rodionova L, Nevzorova V, Soldatova I, Lusanova O, Arandjelovic A, Toncev D, Milanov M, Sekularac N, Zdravkovic M, Hinic S, Dimkovic S, Acimovic T, Saric J, Polovina M, Potpara T, Vujisic-Tesic B, Nedeljkovic M, Zlatar M, Asanin M, Vasic V, Popovic Z, Djikic D, Sipic M, Peric V, Dejanovic B, Milosevic N, Stevanovic A, Andric A, Pencic B, Pavlovic-Kleut M, Celic V, Pavlovic M, Petrovic M, Vuleta M, Petrovic N, Simovic S, Savovic Z, Milanov S, Davidovic G, Iric-Cupic V, Simonovic D, Stojanovic M, Stojanovic S, Mitic V, Ilic V, Petrovic D, Deljanin Ilic M, Ilic S, Stoickov V, Markovic S, Kovacevic S, García Fernandez A, Perez Cabeza A, Anguita M, Tercedor Sanchez L, Mau E, Loayssa J, Ayarra M, Carpintero M, Roldán Rabadan I, Leal M, Gil Ortega M, Tello Montoliu A, Orenes Piñero E, Manzano Fernández S, Marín F, Romero Aniorte A, Veliz Martínez A, Quintana Giner M, Ballesteros G, Palacio M, Alcalde O, García-Bolao I, Bertomeu Gonzalez V, Otero-Raviña F, García Seara J, Gonzalez Juanatey J, Dayal N, Maziarski P, Gentil-Baron P, Shah D, Koç M, Onrat E, Dural IE, Yilmaz K, Özin B, Tan Kurklu S, Atmaca Y, Canpolat U, Tokgozoglu L, Dolu AK, Demirtas B, Sahin D, Ozcan Celebi O, Diker E, Gagirci G, Turk UO, Ari H, Polat N, Toprak N, Sucu M, Akin Serdar O, Taha Alper A, Kepez A, Yuksel Y, Uzunselvi A, Yuksel S, Sahin M, Kayapinar O, Ozcan T, Kaya H, Yilmaz MB, Kutlu M, Demir M, Gibbs C, Kaminskiene S, Bryce M, Skinner A, Belcher G, Hunt J, Stancombe L, Holbrook B, Peters C, Tettersell S, Shantsila A, Lane D, Senoo K, Proietti M, Russell K, Domingos P, Hussain S, Partridge J, Haynes R, Bahadur S, Brown R, McMahon S, Y H Lip G, McDonald J, Balachandran K, Singh R, Garg S, Desai H, Davies K, Goddard W, Galasko G, Rahman I, Chua Y, Payne O, Preston S, Brennan O, Pedley L, Whiteside C, Dickinson C, Brown J, Jones K, Benham L, Brady R, Buchanan L, Ashton A, Crowther H, Fairlamb H, Thornthwaite S, Relph C, McSkeane A, Poultney U, Kelsall N, Rice P, Wilson T, Wrigley M, Kaba R, Patel T, Young E, Law J, Runnett C, Thomas H, McKie H, Fuller J, Pick S, Sharp A, Hunt A, Thorpe K, Hardman C, Cusack E, Adams L, Hough M, Keenan S, Bowring A, Watts J, Zaman J, Goffin K, Nutt H, Beerachee Y, Featherstone J, Mills C, Pearson J, Stephenson L, Grant S, Wilson A, Hawksworth C, Alam I, Robinson M, Ryan S, Egdell R, Gibson E, Holland M, Leonard D, Mishra B, Ahmad S, Randall H, Hill J, Reid L, George M, McKinley S, Brockway L, Milligan W, Sobolewska J, Muir J, Tuckis L, Winstanley L, Jacob P, Kaye S, Morby L, Jan A, Sewell T, Boos C, Wadams B, Cope C, Jefferey P, Andrews N, Getty A, Suttling A, Turner C, Hudson K, Austin R, Howe S, Iqbal R, Gandhi N, Brophy K, Mirza P, Willard E, Collins S, Ndlovu N, Subkovas E, Karthikeyan V, Waggett L, Wood A, Bolger A, Stockport J, Evans L, Harman E, Starling J, Williams L, Saul V, Sinha M, Bell L, Tudgay S, Kemp S, Brown J, Frost L, Ingram T, Loughlin A, Adams C, Adams M, Hurford F, Owen C, Miller C, Donaldson D, Tivenan H, Button H, Nasser A, Jhagra O, Stidolph B, Brown C, Livingstone C, Duffy M, Madgwick P, Roberts P, Greenwood E, Fletcher L, Beveridge M, Earles S, McKenzie D, Beacock D, Dayer M, Seddon M, Greenwell D, Luxton F, Venn F, Mills H, Rewbury J, James K, Roberts K, Tonks L, Felmeden D, Taggu W, Summerhayes A, Hughes D, Sutton J, Felmeden L, Khan M, Walker E, Norris L, O’Donohoe L, Mozid A, Dymond H, Lloyd-Jones H, Saunders G, Simmons D, Coles D, Cotterill D, Beech S, Kidd S, Wrigley B, Petkar S, Smallwood A, Jones R, Radford E, Milgate S, Metherell S, Cottam V, Buckley C, Broadley A, Wood D, Allison J, Rennie K, Balian L, Howard L, Pippard L, Board S, Pitt-Kerby T. Epidemiology and impact of frailty in patients with atrial fibrillation in Europe. Age Ageing 2022; 51:6670566. [PMID: 35997262 DOI: 10.1093/ageing/afac192] [Citation(s) in RCA: 24] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Revised: 06/08/2022] [Indexed: 12/03/2022] Open
Abstract
BACKGROUND Frailty is a medical syndrome characterised by reduced physiological reserve and increased vulnerability to stressors. Data regarding the relationship between frailty and atrial fibrillation (AF) are still inconsistent. OBJECTIVES We aim to perform a comprehensive evaluation of frailty in a large European cohort of AF patients. METHODS A 40-item frailty index (FI) was built according to the accumulation of deficits model in the AF patients enrolled in the ESC-EHRA EORP-AF General Long-Term Registry. Association of baseline characteristics, clinical management, quality of life, healthcare resources use and risk of outcomes with frailty was examined. RESULTS Among 10,177 patients [mean age (standard deviation) 69.0 (11.4) years, 4,103 (40.3%) females], 6,066 (59.6%) were pre-frail and 2,172 (21.3%) were frail, whereas only 1,939 (19.1%) were considered robust. Baseline thromboembolic and bleeding risks were independently associated with increasing FI. Frail patients with AF were less likely to be treated with oral anticoagulants (OACs) (odds ratio 0.70, 95% confidence interval 0.55-0.89), especially with non-vitamin K antagonist OACs and managed with a rhythm control strategy, compared with robust patients. Increasing frailty was associated with a higher risk for all outcomes examined, with a non-linear exponential relationship. The use of OAC was associated with a lower risk of outcomes, except in patients with very/extremely high frailty. CONCLUSIONS In this large cohort of AF patients, there was a high burden of frailty, influencing clinical management and risk of adverse outcomes. The clinical benefit of OAC is maintained in patients with high frailty, but not in very high/extremely frail ones.
Collapse
Affiliation(s)
- Marco Proietti
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.,Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy
| | - Giulio Francesco Romiti
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Translational and Precision Medicine, Sapienza - University of Rome, Italy
| | - Marco Vitolo
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.,Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy
| | - Stephanie L Harrison
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK
| | - Deirdre A Lane
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | - Laurent Fauchier
- Service de Cardiologie, Centre Hospitalier Universitaire Trousseau, Tours, France
| | - Francisco Marin
- Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, IMIB-Arrixaca, University of Murcia, CIBER-CV, Murcia, Spain
| | - Michael Näbauer
- Department of Cardiology, Ludwig-Maximilians-University, Munich, Germany
| | - Tatjana S Potpara
- School of Medicine, University of Belgrade, Belgrade, Serbia.,Clinical Center of Serbia, Belgrade, Serbia
| | - Gheorghe-Andrei Dan
- University of Medicine, 'Carol Davila', Colentina University Hospital, Bucharest, Romania
| | - Aldo P Maggioni
- ANMCO Research Center, Heart Care Foundation, Florence, Italy
| | - Matteo Cesari
- Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.,Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy
| | - Giuseppe Boriani
- Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy
| | - Gregory Y H Lip
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Guido M, Lopes N, Albuquerque C, Tavares E, Jensen L, Carvalho P, Pereira L, Dias R, Laurindo F, Maranhão R. Methotrexate associated with a lipid core nanoparticle prevented the dilation and dissection of the aortic arch in mice with Marfan syndrome. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
3
|
André T, Van Cutsem E, Elez E, Bennouna J, de la Fouchardière C, Yoshino T, Jensen L, Mendez G, Li J, Goekkurt E, Abdullaev S, Chen T, Lei M, Lonardi S. P-12 A phase 3 study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
4
|
Spindler K, Callesen L, Andersen R, Pallisgaard N, Kramer S, Schlander S, Rafaelsen S, Boysen A, Jensen L, Jakobsen A, Hansen T. P-174 OPTIMISE: Optimization of treatment selection and follow-up in oligometastatic colorectal cancer – a ctDNA-guided phase II randomized approach with a run-in feasibility part. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
5
|
Ellegaard K, Guldberg-Møller J, Boesen M, Kristensen LE, Gudbergsen H, Jensen L, Overgaard A, Bliddal H, Henriksen M. POS1107 CHANGE IN ULTRASOUND-BASED KNEE JOINT INFLAMMATORY MARKERS AFTER WEIGHT LOSS IN PATIENTS WITH OSTEOARTHRITIS: A PROSPECTIVE COHORT STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundPain and impaired function due to knee OA (KOA) can be reduced with weight loss in obese patients. The role of synovitis in symptom improvement after weight loss is not fully understood. MRI and ultrasound (US) can be used in assessment of inflammation in the KOA. Knee joint synovitis assessed by MRI does not seem to change with weight loss, however, the typical MRI score is semiquantitative, which might be less sensitive to change than a quantitative score. US has a higher resolution than MRI and borders between synovium and surrounding tissues might be clearer allowing for a quantitative score. Changes in US-based synovitis following a weight has not been assessed.ObjectivesTo assess changes in US synovitis in the knee joint after 8 weeks low-calorie weight loss intervention in overweight persons with KOA.Methodsprospective cohort study (NCT02931370) including overweight persons (BMI ≥ 27 kg/m2) with KOA. Weight loss was induced by an intensive 8-week diet (1200 kcal/day), participants had symptomatic and radiographically confirmed KOA (KL grade 1-3). At week 0 and 8 all participants filled in the KOOS questionnaire assessing pain, physical function, symptoms, quality of life, and sport/recreation in relation to KOA (0= worst; 100=best). Furthermore, an US examination of the most affected knee was performed assessing the amount of synovial hypertrophy (SH) and effusion in medial and lateral recesses. The US examination was performed in a strictly standardized manner on a high-end US machine. The subsequent image evaluation was done both according to a semiquantitative score from 0 to 3 (0=no SH/effusion and 3=pronounced SH/effusion) and a quantitative scoring system using specific anatomic landmarks to measure the synovial hypertrophy/effusion in millimeter.Statistical analyses were performed on the per protocol population (participants completing diet intervention).Results135 patients with KOA with a mean age of 60y (SD 9.8), a body weight of 106.0 kg (SD18.5) and mean BMI of 36.4 (SD5.4) completed the weight loss intervention. After the diet intervention mean weight change was -12.8 kg (95%CI -13.3 to -12.4) and the reductions in SH were -0.3mm (95%CI -0.5 to -0.1) (medial recess) and -0.4mm (95%CI -0.6 to -0.1) (lateral recess), and -0.03 (-0.13 to 0.07) (medial recess) and -0.07 (-0.20 to 0.05) using the semi-quantitative system. The mean change in the KOOS subscales range from 15.8 (sport/recreation) to 7.4 (QoL). See Table 1.Table 1.n=135BaselineChangeMean (SD)Mean (95%CI)PAge60.0 (9.8)--Females, n (%)87 (64.4%)--BMI36.4 (5.4)-4.4 (-4.5 to -4.3)<.0001KL-scores; 122 (16.3%)--KL-scores; 256 (41.5%)--KL-scores; 357 (42.2%)--KL-scores; 40 (0%)--Synovial HypertrophyMedial, mm3.8 (1.8)-0.3 (-0.5 to -0.1)0.0198Lateral, mm5.3 (2.3)-0.4 (-0.6 to -0.1)0.0210Medial, 0-31.2 (0.6)-0.03 (-0.13 to 0.07)0.5584Lateral, 0-31.8 (0.8)-0.07 (-0.20 to 0.05)0.2311KOOS, 0-100Pain64.1 (16.0)12 (10.2 to 13.8)<.0001Function68.4 (17.3)14 (12.4 to 15.6)<.0001Symptoms68.9 (16.4)9 (7.2 to 10.8)<.0001Sports/Recreation35.9 (24.0)15.8 (13.2 to 18.3)<.0001QoL43.8 (17.5)7.4 (5.7 to 9.2)<.0001SD = Standard Deviation; CI = Confidence Interval; BMI = Body Mass Index;KOOS = Knee injury and Osteoarthritis Outcome Score; QoL = Knee-related Quality of LifeConclusionQuantitative measures of SH assessed by US decreased after a significant weight loss over 8-weeks; however, no linear association with weight loss magnitude was seen. A weak correlation between changes in SH in the lateral recess and change in pain was seen. This indicates changes in SH assessed by US examination is associated with a low-calorie diet but seems uncoupled with weight loss magnitude. The weight loss induced changes in synovitis and KOA symptoms seem vaguely related.Disclosure of InterestsNone declared
Collapse
|
6
|
André T, Shiu K, Kim T, Jensen B, Jensen L, Punt C, Smith D, Garcia-Carbonero R, Alcaide García J, Gibbs P, De la Fouchardière C, Rivera Herrero F, Elez E, Bendell J, Le D, Yoshino T, Zhong W, Fogelman D, Marinello P, Diaz L. O-8 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
7
|
|
8
|
Albuquerque C, Tavares E, Guido M, Lopes N, Baroni R, Jensen L, Silva B, Kalil-Filho R, Tavoni T, Maranhao R. Daunorubicin associated to lipid core nanoparticles reduces atherosclerotic lesions, inflammation and cardiotoxicity in atherosclerosis rabbit model. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Antiproliferative agents used in cancer chemotherapy have low toxicity and increased pharmacological action when carried into lipid core nanoparticles (LDE). LDE has similar structure to LDL and binds to LDL receptors through apo E it acquires in contact with plasma. Previously, we showed that treatment of rabbits with atherosclerosis with drugs such as taxanes and etoposide associate to LDE had pronounced reduction of the atherosclerotic lesions. In this study, we hypothesized whether daunorubicin (DNR) that belongs to another class of anti-cancer drugs, with a distinct mechanism of action and that has strong cardiotoxicity could also have effects against atherosclerosis.
Methods
Sixteen New Zealand male rabbits were fed with a 1% cholesterol diet for 8 weeks to induce atherosclerosis. After 4 weeks, the animals were treated weekly with LDE-DNR (6mg/kg, iv, n=9) or with LDE only (n=7). In addition, 3 animals without any intervention were used as a control group. Chow consumption, lipid and hematological profiles, body weight, and echocardiography were evaluated at baseline, pre-treatment and post-treatment. Morphometry and protein expression were performed to analyze the aortas.
Results
There was no difference in food intake and body weight for control, LDE and LDE-DNR groups. Total cholesterol, HDL-C, non-HDL-C and triglycerides increased in LDE and LDE-DNR groups when comparing baseline and post-treatment. Red blood cells decreased in LDE group at post-treatment in comparison to baseline, while LDE-DNR presented no such difference. Regarding aortic lesions of LDE-DNR group was 50% lower than LDE group. The protein expression of the inflammatory markers CD68, TNF-α and IL-6 in LDE-DNR was lower than LDE. Pro-apoptotic factors caspase 3, caspase 9 and BAX were also lower in LDE-DNR compared to LDE. Protein expression of vascular endothelial growth factor (VEGF) and vascular cell adhesion molecule (VCAM) was lower in the LDE-DNR group when compared to the LDE group. To test the cardiotoxicity of LDE-DNR, echocardiography was performed and observed that under LDE-DNR both systolic and diastolic function were preserved with no difference in cardiac mass in LDE-DNR when compared to control and LDE groups. However, LDE showed a significant increase in relative heart weight compared to control while LDE-DNR had no such difference. Treatment with LDE-DNR did not induce observable hematological toxicity.
Conclusion
The treatment with LDE-DNR reduced aortic lesions, diminished inflammatory and pro-apoptotic factors, diminished VCAM expression in the aorta and promoted cardiac preservation in a rabbit atherosclerosis model. In conclusion, LDE-DNR can be eligible for future developments in the quest for novel effective and safe treatments for atherosclerosis.
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): FAPESP (Fundaçao de Amparo a Pesquisa do Estado de Sao Paulo)
Collapse
Affiliation(s)
| | | | | | | | | | - L Jensen
- Heart Institute, Sao Paulo, Brazil
| | | | | | | | | |
Collapse
|
9
|
Guido M, Lopes N, Albuquerque C, Tavares E, Jensen L, Pereira L, Kalil-Filho R, Laurindo F, Maranhao R. Methotrexate associated with a lipid core nanoparticle prevented the dilation and dissection of the aortic arch in mice with Marfan syndrome. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Mutations in the fibrillin-1 gene result in dilation, dissection and rupture of the aorta, the main cause of mortality in patients with Marfan syndrome (MFS). Inflammation is associated with greater susceptibility to dissection and rupture of the aorta. Previously, we showed that methotrexate (MTX) carried in lipid core nanoparticles (LDE) had powerful anti-inflammatory and anti-proliferative effects on rheumatoid arthritis and atherosclerotic lesions induced in rabbits and improved myocardial infarction morphological and functional aspects in rats with ligation of left coronary artery. When MTX is associated to LDE, the uptake of the drug by the cells is increased several-fold, which conceivably endows MTX with enhanced action mechanisms and the drug toxicity is diminished.
Purpose
To investigate whether treatment with LDE-MTX can prevent the development of aortic arch lesions in a murine model of MFS.
Methods
mgΔloxPneo MFS murine model and wild-type mice were allocated in 3 groups of treatment: LDE only; MTX in commercial formulation; LDE-MTX. The treatment occurred weekly at a dose of 1mg/kg ip, between the 3rd and 6th month of life, period in which both dilation and dissection of the aortic arch are observed. After 12 weeks, the animals were submitted to echocardiography, morphometry and protein expression of the aortic arch.
Results
Compared to LDE and MTX groups, LDE-MTX treatment showed smaller lumen area of ascending and descending aorta and aortic arch segments in MFS mice. LDE-MTX also decreased the collagen volume fraction and the amount of aortic dissections, but did not affect the thickness of the vessel wall and the number of elastic fiber ruptures. The protein expression of the inflammatory markers CD68 (macrophages), CD3 (lymphocytes) and tumor necrosis factor alpha, of the apoptotic marker caspase 3 and of type 1 collagen were lower in MFS LDE-MTX group when compared to MFS mice treated with LDE and MTX. Moreover, treatment with LDE-MTX reduced TGF-β, ERK and the SMAD3 protein expression. Of note, CD68 and CD3 protein expression was positively correlated with the lumen area of the aortic arch (r2=0.36; p<0.001), indicating the importance of inflammation for the aortic dilation. The increase in bioavailability of intracellular adenosine in MFS animals treated with LDE-MTX was suggested by the higher expression of A2a adenosine receptor and the lower expression of adenosine deaminase in the aortic arch.
Conclusion
Possibly by increasing the bioavailability of intracellular adenosine, LDE-MTX treatment had the ability to reduce the processes of inflammation, apoptosis and fibrosis that are consequent to fibrillin-1 mutation. By these means, LDE-MTX may conceivably prevent the development of the dilation and dissection in the aortic arch, the hallmarks of MFS, in this animal model.
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo)
Collapse
Affiliation(s)
- M.C Guido
- Heart Institute of the University of Sao Paulo (InCor), Sao Paulo, Brazil
| | - N.M Lopes
- Heart Institute of the University of Sao Paulo (InCor), Sao Paulo, Brazil
| | - C.I Albuquerque
- Heart Institute of the University of Sao Paulo (InCor), Sao Paulo, Brazil
| | - E.R Tavares
- Heart Institute of the University of Sao Paulo (InCor), Sao Paulo, Brazil
| | - L Jensen
- Heart Institute of the University of Sao Paulo (InCor), Sao Paulo, Brazil
| | - L.V Pereira
- University of Sao Paulo, Biosciences Institute, Sao Paulo, Brazil
| | - R Kalil-Filho
- Heart Institute of the University of Sao Paulo (InCor), Sao Paulo, Brazil
| | - F.R.M Laurindo
- Heart Institute of the University of Sao Paulo (InCor), Sao Paulo, Brazil
| | - R.C Maranhao
- Heart Institute of the University of Sao Paulo (InCor), Sao Paulo, Brazil
| |
Collapse
|
10
|
Lopes N, Guido M, Albuquerque C, Jensen L, Miura V, Marinho L, Maranhao R. Treatment with methotrexate carried in lipid core nanoparticles prevents the development of diastolic dysfunction in septic rats. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
In the development of sepsis, besides the dysregulation of the immune system and disturbances of several vital organs, life-threatening cardiac dysfunction often occurs. Previously, we showed that non-protein nanoparticles that resemble the lipid structure of low-density lipoprotein, termed LDE, concentrate in inflammatory sites. When incorporated in LDE, the cellular uptake of MTX increases several-fold compared to the uptake of commercial MTX. The novel LDE-MTX formulation was shown to have the ability to modulate the immune response in in rabbits with atherosclerosis and in rats with myocardial infarction. LDE-MTX reduced the inflammation and improved the post-infarction cardiac function by increasing the release of angiogenesis, thereby improving hypoxia. The aim of the current study was to test the hypothesis whether LDE-MTX could also improve the cardiac status in septic rats.
Methods
Septicemia was induced in Wistar rats by two I.P. injections of lipopolysaccharide (LPS, 10mg/kg) administered with a 24h interval. Rats were allocated to control group (CT, without sepsis; n=5) and 3 groups with sepsis: LDE (n=7), treated with LDE only; MTX (n=6), with commercial MTX (1mg/kg); and LDE-MTX (n=7), with LDE-MTX (1mg/kg). Echocardiography was performed 72h after sepsis induction. Animals were euthanised and LV tissues were collected for protein expression analysis of inflammatory, apoptotic, angiogenesis, hypoxia and adenosine bioavailability markers.
Results
Septic rats treated with LDE developed diastolic dysfunction and presented decreased diastolic volume and diameter of the LV. Treatment with LDE-MTX totally prevented the appearance of diastolic dysfunction and the alterations in LV diastolic dilation. Also, LDE-MTX treatment elicited cardiac hypertrophy through the increase of the thickness of septum and of the LV posterior wall. LDE-MTX increased LV mass and the relative heart weight, as compared to the other 3 groups. There were no differences in the protein expression of inflammatory (lymphocytes, tumor necrosis factor, interleukins) and apoptotic (caspases and B-cell lymphoma family) markers among the four groups. However, LDE-MTX showed higher expression of CD68 (macrophage marker). Angiogenesis was higher, while cellular hypoxia was lower in LDE-MTX, respectively represented by vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1 alpha, in comparison to the other 3 groups. The intracellular adenosine bioavailability was increased in LDE-MTX-treated animals, as promoted by the higher expression of the A1 receptor, as compared to CT.
Conclusion
The treatment with LDE-MTX was successful in precluding the appearance of the cardiac dysfunction associated to sepsis. This outcome was conceivably attained by different effects of the treatment observed here, such as those on angiogenesis, macrophage recruitment and adenosine bioavailability in the LV.
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo)
Collapse
Affiliation(s)
- N.M Lopes
- Heart Institute of the University of Sao Paulo (InCor), Sao Paulo, Brazil
| | - M.C Guido
- Heart Institute of the University of Sao Paulo (InCor), Sao Paulo, Brazil
| | - C.I Albuquerque
- Heart Institute of the University of Sao Paulo (InCor), Sao Paulo, Brazil
| | - L Jensen
- Heart Institute of the University of Sao Paulo (InCor), Sao Paulo, Brazil
| | - V.M Miura
- Heart Institute of the University of Sao Paulo (InCor), Sao Paulo, Brazil
| | - L.M Marinho
- Heart Institute of the University of Sao Paulo (InCor), Sao Paulo, Brazil
| | - R.C Maranhao
- Heart Institute of the University of Sao Paulo (InCor), Sao Paulo, Brazil
| |
Collapse
|
11
|
Charles L, Jensen L, Torti JMI, Parmar J, Dobbs B, Tian PGJ. Improving transitions from acute care to home among complex older adults using the LACE Index and care coordination. BMJ Open Qual 2020; 9:bmjoq-2019-000814. [PMID: 32565420 PMCID: PMC7311032 DOI: 10.1136/bmjoq-2019-000814] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2019] [Revised: 05/29/2020] [Accepted: 06/02/2020] [Indexed: 11/04/2022] Open
Abstract
BACKGROUND Improving transitions in care is a major focus of healthcare planning. The objective of this study was to determine the improvement in transitions from an intervention identifying complex older adult patients in acute care and supporting their discharge into the community. METHODS This was a quality assurance study evaluating an intervention on high-risk patients admitted in an acute care hospital. In phase 1, the Length of Stay, Acuity of the Admission, Charlson Comorbidity Index Score, and Emergency Department Use (LACE Index) was selected to assess a patient's risk for readmission and a standard discharge protocol was developed. In phase 2, the intervention was implemented: (1) all patients were screened for the risk of readmission using the LACE Index; and (2) the high-risk patients were provided care coordination including follow-up phone calls focused on medications, equipment and homecare services. Emergency department (ED) revisits and hospital readmissions were measured. RESULTS The LACE Index identified 433/1621 (27%) patients at high risk for readmission. Care coordination was achieved within 72 hours in 79% of patients. The 433 high-risk patients receiving the intervention, compared with a group without intervention (n=231), had lower lengths of stay (12.7 days vs 16.6 days); similar 7-day ED revisits (10.6% vs 10.8%) and 30-day ED revisits (30.5% vs 33.3%); lower 90-day readmissions (39.3% vs 44.6%); and lower 6-month readmissions (50.9% vs 58.4%). The 7-day and 30-day readmissions were similar in both groups. CONCLUSIONS Identifying complex patients at high risk for readmission and supporting them during transitions from acute care to home potentially decreases lengths of hospital stay and prevents short-term ED revisits and long-term readmissions.
Collapse
Affiliation(s)
- Lesley Charles
- Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada
| | - Lisa Jensen
- Integrated Access, Covenant Health, Edmonton, Alberta, Canada
| | - Jacqueline M I Torti
- Centre for Education Research and Innovation, Western University, London, Ontario, Canada
| | - Jasneet Parmar
- Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada
| | - Bonnie Dobbs
- Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada
| | | |
Collapse
|
12
|
Aprà E, Bylaska EJ, de Jong WA, Govind N, Kowalski K, Straatsma TP, Valiev M, van Dam HJJ, Alexeev Y, Anchell J, Anisimov V, Aquino FW, Atta-Fynn R, Autschbach J, Bauman NP, Becca JC, Bernholdt DE, Bhaskaran-Nair K, Bogatko S, Borowski P, Boschen J, Brabec J, Bruner A, Cauët E, Chen Y, Chuev GN, Cramer CJ, Daily J, Deegan MJO, Dunning TH, Dupuis M, Dyall KG, Fann GI, Fischer SA, Fonari A, Früchtl H, Gagliardi L, Garza J, Gawande N, Ghosh S, Glaesemann K, Götz AW, Hammond J, Helms V, Hermes ED, Hirao K, Hirata S, Jacquelin M, Jensen L, Johnson BG, Jónsson H, Kendall RA, Klemm M, Kobayashi R, Konkov V, Krishnamoorthy S, Krishnan M, Lin Z, Lins RD, Littlefield RJ, Logsdail AJ, Lopata K, Ma W, Marenich AV, Martin Del Campo J, Mejia-Rodriguez D, Moore JE, Mullin JM, Nakajima T, Nascimento DR, Nichols JA, Nichols PJ, Nieplocha J, Otero-de-la-Roza A, Palmer B, Panyala A, Pirojsirikul T, Peng B, Peverati R, Pittner J, Pollack L, Richard RM, Sadayappan P, Schatz GC, Shelton WA, Silverstein DW, Smith DMA, Soares TA, Song D, Swart M, Taylor HL, Thomas GS, Tipparaju V, Truhlar DG, Tsemekhman K, Van Voorhis T, Vázquez-Mayagoitia Á, Verma P, Villa O, Vishnu A, Vogiatzis KD, Wang D, Weare JH, Williamson MJ, Windus TL, Woliński K, Wong AT, Wu Q, Yang C, Yu Q, Zacharias M, Zhang Z, Zhao Y, Harrison RJ. NWChem: Past, present, and future. J Chem Phys 2020; 152:184102. [PMID: 32414274 DOI: 10.1063/5.0004997] [Citation(s) in RCA: 275] [Impact Index Per Article: 68.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Specialized computational chemistry packages have permanently reshaped the landscape of chemical and materials science by providing tools to support and guide experimental efforts and for the prediction of atomistic and electronic properties. In this regard, electronic structure packages have played a special role by using first-principle-driven methodologies to model complex chemical and materials processes. Over the past few decades, the rapid development of computing technologies and the tremendous increase in computational power have offered a unique chance to study complex transformations using sophisticated and predictive many-body techniques that describe correlated behavior of electrons in molecular and condensed phase systems at different levels of theory. In enabling these simulations, novel parallel algorithms have been able to take advantage of computational resources to address the polynomial scaling of electronic structure methods. In this paper, we briefly review the NWChem computational chemistry suite, including its history, design principles, parallel tools, current capabilities, outreach, and outlook.
Collapse
Affiliation(s)
- E Aprà
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - E J Bylaska
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - W A de Jong
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - N Govind
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - K Kowalski
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - T P Straatsma
- National Center for Computational Sciences, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - M Valiev
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - H J J van Dam
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Y Alexeev
- Argonne Leadership Computing Facility, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - J Anchell
- Intel Corporation, Santa Clara, California 95054, USA
| | - V Anisimov
- Argonne Leadership Computing Facility, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - F W Aquino
- QSimulate, Cambridge, Massachusetts 02139, USA
| | - R Atta-Fynn
- Department of Physics, The University of Texas at Arlington, Arlington, Texas 76019, USA
| | - J Autschbach
- Department of Chemistry, University at Buffalo, State University of New York, Buffalo, New York 14260, USA
| | - N P Bauman
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - J C Becca
- Department of Chemistry, The Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - D E Bernholdt
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | | | - S Bogatko
- 4G Clinical, Wellesley, Massachusetts 02481, USA
| | - P Borowski
- Faculty of Chemistry, Maria Curie-Skłodowska University in Lublin, 20-031 Lublin, Poland
| | - J Boschen
- Department of Chemistry, Iowa State University, Ames, Iowa 50011, USA
| | - J Brabec
- J. Heyrovský Institute of Physical Chemistry, Academy of Sciences of the Czech Republic, 18223 Prague 8, Czech Republic
| | - A Bruner
- Department of Chemistry and Physics, University of Tennessee at Martin, Martin, Tennessee 38238, USA
| | - E Cauët
- Service de Chimie Quantique et Photophysique (CP 160/09), Université libre de Bruxelles, B-1050 Brussels, Belgium
| | - Y Chen
- Facebook, Menlo Park, California 94025, USA
| | - G N Chuev
- Institute of Theoretical and Experimental Biophysics, Russian Academy of Science, Pushchino, Moscow Region 142290, Russia
| | - C J Cramer
- Department of Chemistry, Chemical Theory Center, and Supercomputing Institute, University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - J Daily
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - M J O Deegan
- SKAO, Jodrell Bank Observatory, Macclesfield SK11 9DL, United Kingdom
| | - T H Dunning
- Department of Chemistry, University of Washington, Seattle, Washington 98195, USA
| | - M Dupuis
- Department of Chemistry, University at Buffalo, State University of New York, Buffalo, New York 14260, USA
| | - K G Dyall
- Dirac Solutions, Portland, Oregon 97229, USA
| | - G I Fann
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - S A Fischer
- Chemistry Division, U. S. Naval Research Laboratory, Washington, DC 20375, USA
| | - A Fonari
- School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia 30332, USA
| | - H Früchtl
- EaStCHEM and School of Chemistry, University of St. Andrews, St. Andrews KY16 9ST, United Kingdom
| | - L Gagliardi
- Department of Chemistry, Chemical Theory Center, and Supercomputing Institute, University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - J Garza
- Departamento de Química, División de Ciencias Básicas e Ingeniería, Universidad Autónoma Metropolitana-Iztapalapa, Col. Vicentina, Iztapalapa, C.P. 09340 Ciudad de México, Mexico
| | - N Gawande
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - S Ghosh
- Department of Chemistry, Chemical Theory Center, and Supercomputing Institute, University of Minnesota, Minneapolis, Minnesota 5545, USA
| | - K Glaesemann
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - A W Götz
- San Diego Supercomputer Center, University of California, San Diego, La Jolla, California 92093, USA
| | - J Hammond
- Intel Corporation, Santa Clara, California 95054, USA
| | - V Helms
- Center for Bioinformatics, Saarland University, D-66041 Saarbrücken, Germany
| | - E D Hermes
- Combustion Research Facility, Sandia National Laboratories, Livermore, California 94551, USA
| | - K Hirao
- Next-generation Molecular Theory Unit, Advanced Science Institute, RIKEN, Saitama 351-0198, Japan
| | - S Hirata
- Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - M Jacquelin
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - L Jensen
- Department of Chemistry, The Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - B G Johnson
- Acrobatiq, Pittsburgh, Pennsylvania 15206, USA
| | - H Jónsson
- Faculty of Physical Sciences, University of Iceland, Reykjavík, Iceland and Department of Applied Physics, Aalto University, FI-00076 Aalto, Espoo, Finland
| | - R A Kendall
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - M Klemm
- Intel Corporation, Santa Clara, California 95054, USA
| | - R Kobayashi
- ANU Supercomputer Facility, Australian National University, Canberra, Australia
| | - V Konkov
- Chemistry Program, Florida Institute of Technology, Melbourne, Florida 32901, USA
| | - S Krishnamoorthy
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - M Krishnan
- Facebook, Menlo Park, California 94025, USA
| | - Z Lin
- Department of Physics, University of Science and Technology of China, Hefei, China
| | - R D Lins
- Aggeu Magalhaes Institute, Oswaldo Cruz Foundation, Recife, Brazil
| | | | - A J Logsdail
- Cardiff Catalysis Institute, School of Chemistry, Cardiff University, Cardiff, Wales CF10 3AT, United Kingdom
| | - K Lopata
- Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803, USA
| | - W Ma
- Institute of Software, Chinese Academy of Sciences, Beijing, China
| | - A V Marenich
- Department of Chemistry, Chemical Theory Center, and Supercomputing Institute, University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - J Martin Del Campo
- Departamento de Física y Química Teórica, Facultad de Química, Universidad Nacional Autónoma de México, México City, Mexico
| | - D Mejia-Rodriguez
- Quantum Theory Project, Department of Physics, University of Florida, Gainesville, Florida 32611, USA
| | - J E Moore
- Intel Corporation, Santa Clara, California 95054, USA
| | - J M Mullin
- DCI-Solutions, Aberdeen Proving Ground, Maryland 21005, USA
| | - T Nakajima
- Computational Molecular Science Research Team, RIKEN Center for Computational Science, Kobe, Hyogo 650-0047, Japan
| | - D R Nascimento
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - J A Nichols
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - P J Nichols
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - J Nieplocha
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - A Otero-de-la-Roza
- Departamento de Química Física y Analítica, Facultad de Química, Universidad de Oviedo, 33006 Oviedo, Spain
| | - B Palmer
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - A Panyala
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - T Pirojsirikul
- Department of Chemistry, Prince of Songkla University, Hat Yai, Songkhla 90112, Thailand
| | - B Peng
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - R Peverati
- Chemistry Program, Florida Institute of Technology, Melbourne, Florida 32901, USA
| | - J Pittner
- J. Heyrovský Institute of Physical Chemistry, Academy of Sciences of the Czech Republic, v.v.i., 18223 Prague 8, Czech Republic
| | - L Pollack
- StudyPoint, Boston, Massachusetts 02114, USA
| | | | - P Sadayappan
- School of Computing, University of Utah, Salt Lake City, Utah 84112, USA
| | - G C Schatz
- Department of Chemistry, Northwestern University, Evanston, Illinois 60208, USA
| | - W A Shelton
- Cain Department of Chemical Engineering, Louisiana State University, Baton Rouge, Louisiana 70803, USA
| | | | - D M A Smith
- Intel Corporation, Santa Clara, California 95054, USA
| | - T A Soares
- Dept. of Fundamental Chemistry, Universidade Federal de Pernambuco, Recife, Brazil
| | - D Song
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - M Swart
- ICREA, 08010 Barcelona, Spain and Universitat Girona, Institut de Química Computacional i Catàlisi, Campus Montilivi, 17003 Girona, Spain
| | - H L Taylor
- CD-adapco/Siemens, Melville, New York 11747, USA
| | - G S Thomas
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - V Tipparaju
- Cray Inc., Bloomington, Minnesota 55425, USA
| | - D G Truhlar
- Department of Chemistry, Chemical Theory Center, and Supercomputing Institute, University of Minnesota, Minneapolis, Minnesota 55455, USA
| | | | - T Van Voorhis
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - Á Vázquez-Mayagoitia
- Argonne Leadership Computing Facility, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - P Verma
- 1QBit, Vancouver, British Columbia V6E 4B1, Canada
| | - O Villa
- NVIDIA, Santa Clara, California 95051, USA
| | - A Vishnu
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - K D Vogiatzis
- Department of Chemistry, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - D Wang
- College of Physics and Electronics, Shandong Normal University, Jinan, Shandong 250014, China
| | - J H Weare
- Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California 92093, USA
| | - M J Williamson
- Department of Chemistry, Cambridge University, Lensfield Road, Cambridge CB2 1EW, United Kingdom
| | - T L Windus
- Department of Chemistry, Iowa State University and Ames Laboratory, Ames, Iowa 50011, USA
| | - K Woliński
- Faculty of Chemistry, Maria Curie-Skłodowska University in Lublin, 20-031 Lublin, Poland
| | - A T Wong
- Qwil, San Francisco, California 94107, USA
| | - Q Wu
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C Yang
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - Q Yu
- AMD, Santa Clara, California 95054, USA
| | - M Zacharias
- Department of Physics, Technical University of Munich, 85748 Garching, Germany
| | - Z Zhang
- Stanford Research Computing Center, Stanford University, Stanford, California 94305, USA
| | - Y Zhao
- State Key Laboratory of Silicate Materials for Architectures, International School of Materials Science and Engineering, Wuhan University of Technology, Wuhan 430070, China
| | - R J Harrison
- Institute for Advanced Computational Science, Stony Brook University, Stony Brook, New York 11794, USA
| |
Collapse
|
13
|
Jensen L, Bøggild H, Overgaard C, Fonager K. The effect of breast cancer on work participation in different sectors. A Danish registry based study. Eur J Public Health 2019. [DOI: 10.1093/eurpub/ckz185.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
A breast cancer diagnosis affects an individual’s affiliation to the labor market, but whether the effect of breast cancer variates in different sectors in a Danish setting has not been examined. The present study investigated the effect of stage IA breast cancer (tumor<20 mm and no lymph nodes involved in six sectors among Danish women being part of the work force. Stage IA breast cancer has a good prognosis, and it would be assumed that the majority have returned to work after 1 year.
Methods
This registry-based cohort study was based on data from linked Danish nationwide registries. We identified 5,543 women (aged 25-63 years) diagnosed with breast cancer (BC) stage IA (exposed) and 65.889 women without breast cancer (unexposed) and included women from the different sectors. We calculated a yearly Work Participation Score (WPS), defined as the proportion of weeks being self-supported during a year. We compared the means of WPS for exposed and unexposed women in six different sectors: 1) teaching, 2) childcare, 3) eldercare, 4) cleaning, 5) administration and 6) hospitality industry.
Results
BC had a negative effect on being self-supporting for women in all six sectors in all three years, although the effect declined. In the first year, the difference in WPS varied between 0.38 and 0.54. During the second year all BC patients had still significantly lower WPS with the largest difference in hospitality industry (0.65 (95% CI 0.50-0.80) for exposed women and 0.86 (95% CI 0.83-0.88) for unexposed women). In the third year, the effect further declined although WPS was still significantly lower for most sectors with the biggest difference in the cleaning sector.
Conclusions
A stage IA BC diagnosis had a negative effect on being self-supportive after 2 and 3 years among women in all six sectors, although the difference was largest among cleaning workers. This may indicate, that individual follow-up in relation to work participation is necessary.
Key messages
Although breast cancer stage IA has a good prognosis, it still affects being self-supporting after three years. A diagnosis of breast cancer affects the affiliation to the labour market, but the effect differs according to different sectors.
Collapse
Affiliation(s)
- L Jensen
- Department of Social Medicine, Social Medicinsk Afdeling, Aalborg Sygehus, Aalborg, Denmark
| | - H Bøggild
- Public Health and Epidemiology Group, Department of Health, Science and Technology, Aalborg University, Aalborg, Denmark
| | - C Overgaard
- Public Health and Epidemiology Group, Department of Health, Science and Technology, Aalborg University, Aalborg, Denmark
| | - K Fonager
- Department of Social Medicine, Social Medicinsk Afdeling, Aalborg Sygehus, Aalborg, Denmark
- Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| |
Collapse
|
14
|
Adli E, Ahuja A, Apsimon O, Apsimon R, Bachmann AM, Barrientos D, Barros MM, Batkiewicz J, Batsch F, Bauche J, Berglyd Olsen VK, Bernardini M, Biskup B, Boccardi A, Bogey T, Bohl T, Bracco C, Braunmüller F, Burger S, Burt G, Bustamante S, Buttenschön B, Caldwell A, Cascella M, Chappell J, Chevallay E, Chung M, Cooke D, Damerau H, Deacon L, Deubner LH, Dexter A, Doebert S, Farmer J, Fedosseev VN, Fior G, Fiorito R, Fonseca RA, Friebel F, Garolfi L, Gessner S, Gorgisyan I, Gorn AA, Granados E, Grulke O, Gschwendtner E, Guerrero A, Hansen J, Helm A, Henderson JR, Hessler C, Hofle W, Hüther M, Ibison M, Jensen L, Jolly S, Keeble F, Kim SY, Kraus F, Lefevre T, LeGodec G, Li Y, Liu S, Lopes N, Lotov KV, Maricalva Brun L, Martyanov M, Mazzoni S, Medina Godoy D, Minakov VA, Mitchell J, Molendijk JC, Mompo R, Moody JT, Moreira M, Muggli P, Mutin C, Öz E, Ozturk E, Pasquino C, Pardons A, Peña Asmus F, Pepitone K, Perera A, Petrenko A, Pitman S, Plyushchev G, Pukhov A, Rey S, Rieger K, Ruhl H, Schmidt JS, Shalimova IA, Shaposhnikova E, Sherwood P, Silva LO, Soby L, Sosedkin AP, Speroni R, Spitsyn RI, Tuev PV, Turner M, Velotti F, Verra L, Verzilov VA, Vieira J, Vincke H, Welsch CP, Williamson B, Wing M, Woolley B, Xia G. Experimental Observation of Proton Bunch Modulation in a Plasma at Varying Plasma Densities. Phys Rev Lett 2019; 122:054802. [PMID: 30822008 DOI: 10.1103/physrevlett.122.054802] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/05/2018] [Indexed: 06/09/2023]
Abstract
We give direct experimental evidence for the observation of the full transverse self-modulation of a long, relativistic proton bunch propagating through a dense plasma. The bunch exits the plasma with a periodic density modulation resulting from radial wakefield effects. We show that the modulation is seeded by a relativistic ionization front created using an intense laser pulse copropagating with the proton bunch. The modulation extends over the length of the proton bunch following the seed point. By varying the plasma density over one order of magnitude, we show that the modulation frequency scales with the expected dependence on the plasma density, i.e., it is equal to the plasma frequency, as expected from theory.
Collapse
Affiliation(s)
- E Adli
- University of Oslo, 0316 Oslo, Norway
| | - A Ahuja
- CERN, 1211 Geneva, Switzerland
| | - O Apsimon
- University of Manchester, M13 9PL Manchester, United Kingdom
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
| | - R Apsimon
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
- Lancaster University, LA1 4YB Lancaster, United Kingdom
| | - A-M Bachmann
- CERN, 1211 Geneva, Switzerland
- Max Planck Institute for Physics, 80805 Munich, Germany
- Technical University Munich, 80333 Munich, Germany
| | | | | | | | - F Batsch
- CERN, 1211 Geneva, Switzerland
- Max Planck Institute for Physics, 80805 Munich, Germany
- Technical University Munich, 80333 Munich, Germany
| | | | | | | | | | | | - T Bogey
- CERN, 1211 Geneva, Switzerland
| | - T Bohl
- CERN, 1211 Geneva, Switzerland
| | | | - F Braunmüller
- Max Planck Institute for Physics, 80805 Munich, Germany
| | | | - G Burt
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
- Lancaster University, LA1 4YB Lancaster, United Kingdom
| | | | - B Buttenschön
- Max Planck Institute for Plasma Physics, 17491 Greifswald, Germany
| | - A Caldwell
- Max Planck Institute for Physics, 80805 Munich, Germany
| | | | | | | | - M Chung
- UNIST, 44919 Ulsan, Republic of Korea
| | - D Cooke
- UCL, WC1E 6BT London, United Kingdom
| | | | - L Deacon
- UCL, WC1E 6BT London, United Kingdom
| | - L H Deubner
- Philipps-Universität Marburg, 35032 Marburg, Germany
| | - A Dexter
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
- Lancaster University, LA1 4YB Lancaster, United Kingdom
| | | | - J Farmer
- Heinrich-Heine-University of Düsseldorf, 40225 Düsseldorf, Germany
| | | | - G Fior
- Max Planck Institute for Physics, 80805 Munich, Germany
| | - R Fiorito
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
- University of Liverpool, L69 7ZE Liverpool, United Kingdom
| | - R A Fonseca
- ISCTE-Instituto Universitéario de Lisboa, 1649-026 Lisbon, Portugal
| | | | | | | | | | - A A Gorn
- Budker Institute of Nuclear Physics SB RAS, 630090 Novosibirsk, Russia
- Novosibirsk State University, 630090 Novosibirsk, Russia
| | | | - O Grulke
- Max Planck Institute for Plasma Physics, 17491 Greifswald, Germany
- Technical University of Denmark, 2800 Lyngby, Denmark
| | | | | | | | - A Helm
- GoLP/Instituto de Plasmas e Fusão Nuclear, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisbon, Portugal
| | - J R Henderson
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
- Lancaster University, LA1 4YB Lancaster, United Kingdom
| | | | - W Hofle
- CERN, 1211 Geneva, Switzerland
| | - M Hüther
- Max Planck Institute for Physics, 80805 Munich, Germany
| | - M Ibison
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
- University of Liverpool, L69 7ZE Liverpool, United Kingdom
| | | | - S Jolly
- UCL, WC1E 6BT London, United Kingdom
| | - F Keeble
- UCL, WC1E 6BT London, United Kingdom
| | - S-Y Kim
- UNIST, 44919 Ulsan, Republic of Korea
| | - F Kraus
- Philipps-Universität Marburg, 35032 Marburg, Germany
| | | | | | - Y Li
- University of Manchester, M13 9PL Manchester, United Kingdom
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
| | - S Liu
- TRIUMF, V6T 2A3 Vancouver, Canada
| | - N Lopes
- GoLP/Instituto de Plasmas e Fusão Nuclear, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisbon, Portugal
| | - K V Lotov
- Budker Institute of Nuclear Physics SB RAS, 630090 Novosibirsk, Russia
- Novosibirsk State University, 630090 Novosibirsk, Russia
| | | | - M Martyanov
- Max Planck Institute for Physics, 80805 Munich, Germany
| | | | | | - V A Minakov
- Budker Institute of Nuclear Physics SB RAS, 630090 Novosibirsk, Russia
- Novosibirsk State University, 630090 Novosibirsk, Russia
| | - J Mitchell
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
- Lancaster University, LA1 4YB Lancaster, United Kingdom
| | | | - R Mompo
- CERN, 1211 Geneva, Switzerland
| | - J T Moody
- Max Planck Institute for Physics, 80805 Munich, Germany
| | - M Moreira
- CERN, 1211 Geneva, Switzerland
- GoLP/Instituto de Plasmas e Fusão Nuclear, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisbon, Portugal
| | - P Muggli
- CERN, 1211 Geneva, Switzerland
- Max Planck Institute for Physics, 80805 Munich, Germany
| | - C Mutin
- CERN, 1211 Geneva, Switzerland
| | - E Öz
- Max Planck Institute for Physics, 80805 Munich, Germany
| | | | | | | | - F Peña Asmus
- Max Planck Institute for Physics, 80805 Munich, Germany
- Technical University Munich, 80333 Munich, Germany
| | | | - A Perera
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
- University of Liverpool, L69 7ZE Liverpool, United Kingdom
| | - A Petrenko
- CERN, 1211 Geneva, Switzerland
- Budker Institute of Nuclear Physics SB RAS, 630090 Novosibirsk, Russia
| | - S Pitman
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
- Lancaster University, LA1 4YB Lancaster, United Kingdom
| | | | - A Pukhov
- Heinrich-Heine-University of Düsseldorf, 40225 Düsseldorf, Germany
| | - S Rey
- CERN, 1211 Geneva, Switzerland
| | - K Rieger
- Max Planck Institute for Physics, 80805 Munich, Germany
| | - H Ruhl
- Ludwig-Maximilians-Universität, 80539 Munich, Germany
| | | | - I A Shalimova
- Novosibirsk State University, 630090 Novosibirsk, Russia
- Institute of Computational Mathematics and Mathematical Geophysics SB RAS, 630090 Novosibirsk, Russia
| | | | | | - L O Silva
- GoLP/Instituto de Plasmas e Fusão Nuclear, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisbon, Portugal
| | - L Soby
- CERN, 1211 Geneva, Switzerland
| | - A P Sosedkin
- Budker Institute of Nuclear Physics SB RAS, 630090 Novosibirsk, Russia
- Novosibirsk State University, 630090 Novosibirsk, Russia
| | | | - R I Spitsyn
- Budker Institute of Nuclear Physics SB RAS, 630090 Novosibirsk, Russia
- Novosibirsk State University, 630090 Novosibirsk, Russia
| | - P V Tuev
- Budker Institute of Nuclear Physics SB RAS, 630090 Novosibirsk, Russia
- Novosibirsk State University, 630090 Novosibirsk, Russia
| | | | | | - L Verra
- CERN, 1211 Geneva, Switzerland
- University of Milan, 20122 Milan, Italy
| | | | - J Vieira
- GoLP/Instituto de Plasmas e Fusão Nuclear, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisbon, Portugal
| | | | - C P Welsch
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
- University of Liverpool, L69 7ZE Liverpool, United Kingdom
| | - B Williamson
- University of Manchester, M13 9PL Manchester, United Kingdom
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
| | - M Wing
- UCL, WC1E 6BT London, United Kingdom
| | | | - G Xia
- University of Manchester, M13 9PL Manchester, United Kingdom
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
| |
Collapse
|
15
|
Turner M, Adli E, Ahuja A, Apsimon O, Apsimon R, Bachmann AM, Barros Marin M, Barrientos D, Batsch F, Batkiewicz J, Bauche J, Berglyd Olsen VK, Bernardini M, Biskup B, Boccardi A, Bogey T, Bohl T, Bracco C, Braunmüller F, Burger S, Burt G, Bustamante S, Buttenschön B, Caldwell A, Cascella M, Chappell J, Chevallay E, Chung M, Cooke D, Damerau H, Deacon L, Deubner LH, Dexter A, Doebert S, Farmer J, Fedosseev VN, Fior G, Fiorito R, Fonseca RA, Friebel F, Garolfi L, Gessner S, Gorgisyan I, Gorn AA, Granados E, Grulke O, Gschwendtner E, Guerrero A, Hansen J, Helm A, Henderson JR, Hessler C, Hofle W, Hüther M, Ibison M, Jensen L, Jolly S, Keeble F, Kim SY, Kraus F, Lefevre T, LeGodec G, Li Y, Liu S, Lopes N, Lotov KV, Maricalva Brun L, Martyanov M, Mazzoni S, Medina Godoy D, Minakov VA, Mitchell J, Molendijk JC, Mompo R, Moody JT, Moreira M, Muggli P, Öz E, Ozturk E, Mutin C, Pasquino C, Pardons A, Peña Asmus F, Pepitone K, Perera A, Petrenko A, Pitman S, Plyushchev G, Pukhov A, Rey S, Rieger K, Ruhl H, Schmidt JS, Shalimova IA, Shaposhnikova E, Sherwood P, Silva LO, Soby L, Sosedkin AP, Speroni R, Spitsyn RI, Tuev PV, Velotti F, Verra L, Verzilov VA, Vieira J, Vincke H, Welsch CP, Williamson B, Wing M, Woolley B, Xia G. Experimental Observation of Plasma Wakefield Growth Driven by the Seeded Self-Modulation of a Proton Bunch. Phys Rev Lett 2019; 122:054801. [PMID: 30822039 DOI: 10.1103/physrevlett.122.054801] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/04/2018] [Indexed: 06/09/2023]
Abstract
We measure the effects of transverse wakefields driven by a relativistic proton bunch in plasma with densities of 2.1×10^{14} and 7.7×10^{14} electrons/cm^{3}. We show that these wakefields periodically defocus the proton bunch itself, consistently with the development of the seeded self-modulation process. We show that the defocusing increases both along the bunch and along the plasma by using time resolved and time-integrated measurements of the proton bunch transverse distribution. We evaluate the transverse wakefield amplitudes and show that they exceed their seed value (<15 MV/m) and reach over 300 MV/m. All these results confirm the development of the seeded self-modulation process, a necessary condition for external injection of low energy and acceleration of electrons to multi-GeV energy levels.
Collapse
Affiliation(s)
| | - E Adli
- University of Oslo, 0316 Oslo, Norway
| | - A Ahuja
- CERN, 1211 Geneva, Switzerland
| | - O Apsimon
- University of Manchester, M13 9PL Manchester, United Kingdom
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
| | - R Apsimon
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
- Lancaster University, LA1 4YB Lancaster, United Kingdom
| | - A-M Bachmann
- CERN, 1211 Geneva, Switzerland
- Max Planck Institute for Physics, 80805 Munich, Germany
- Technical University Munich, 80333 Munich, Germany
| | | | | | - F Batsch
- CERN, 1211 Geneva, Switzerland
- Max Planck Institute for Physics, 80805 Munich, Germany
- Technical University Munich, 80333 Munich, Germany
| | | | | | | | | | | | | | - T Bogey
- CERN, 1211 Geneva, Switzerland
| | - T Bohl
- CERN, 1211 Geneva, Switzerland
| | | | - F Braunmüller
- Max Planck Institute for Physics, 80805 Munich, Germany
| | | | - G Burt
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
- Lancaster University, LA1 4YB Lancaster, United Kingdom
| | | | - B Buttenschön
- Max Planck Institute for Plasma Physics, 17491 Greifswald, Germany
| | - A Caldwell
- Max Planck Institute for Physics, 80805 Munich, Germany
| | | | | | | | - M Chung
- UNIST, 44919 Ulsan, Republic of Korea
| | - D Cooke
- UCL, WC1E 6BT London, United Kingdom
| | | | - L Deacon
- UCL, WC1E 6BT London, United Kingdom
| | - L H Deubner
- Philipps-Universität Marburg, 35032 Marburg, Germany
| | - A Dexter
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
- Lancaster University, LA1 4YB Lancaster, United Kingdom
| | | | - J Farmer
- Heinrich-Heine-University of Düsseldorf, 40225 Düsseldorf, Germany
| | | | - G Fior
- Max Planck Institute for Physics, 80805 Munich, Germany
| | - R Fiorito
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
- University of Liverpool, L69 7ZE Liverpool, United Kingdom
| | - R A Fonseca
- ISCTE-Instituto Universitéario de Lisboa, 1649-026 Lisbon, Portugal
| | | | | | | | | | - A A Gorn
- Budker Institute of Nuclear Physics SB RAS, 630090 Novosibirsk, Russia
- Novosibirsk State University, 630090 Novosibirsk, Russia
| | | | - O Grulke
- Max Planck Institute for Plasma Physics, 17491 Greifswald, Germany
- Technical University of Denmark, 2800 Lyngby, Denmark
| | | | | | | | - A Helm
- GoLP/Instituto de Plasmas e Fusão Nuclear, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisbon, Portugal
| | - J R Henderson
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
- Lancaster University, LA1 4YB Lancaster, United Kingdom
| | | | - W Hofle
- CERN, 1211 Geneva, Switzerland
| | - M Hüther
- Max Planck Institute for Physics, 80805 Munich, Germany
| | - M Ibison
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
- University of Liverpool, L69 7ZE Liverpool, United Kingdom
| | | | - S Jolly
- UCL, WC1E 6BT London, United Kingdom
| | - F Keeble
- UCL, WC1E 6BT London, United Kingdom
| | - S-Y Kim
- UNIST, 44919 Ulsan, Republic of Korea
| | - F Kraus
- Philipps-Universität Marburg, 35032 Marburg, Germany
| | | | | | - Y Li
- University of Manchester, M13 9PL Manchester, United Kingdom
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
| | - S Liu
- TRIUMF, V6T 2A3 Vancouver, Canada
| | - N Lopes
- GoLP/Instituto de Plasmas e Fusão Nuclear, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisbon, Portugal
| | - K V Lotov
- Budker Institute of Nuclear Physics SB RAS, 630090 Novosibirsk, Russia
- Novosibirsk State University, 630090 Novosibirsk, Russia
| | | | - M Martyanov
- Max Planck Institute for Physics, 80805 Munich, Germany
| | | | | | - V A Minakov
- Budker Institute of Nuclear Physics SB RAS, 630090 Novosibirsk, Russia
- Novosibirsk State University, 630090 Novosibirsk, Russia
| | - J Mitchell
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
- Lancaster University, LA1 4YB Lancaster, United Kingdom
| | | | - R Mompo
- CERN, 1211 Geneva, Switzerland
| | - J T Moody
- Max Planck Institute for Physics, 80805 Munich, Germany
| | - M Moreira
- CERN, 1211 Geneva, Switzerland
- GoLP/Instituto de Plasmas e Fusão Nuclear, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisbon, Portugal
| | - P Muggli
- CERN, 1211 Geneva, Switzerland
- Max Planck Institute for Physics, 80805 Munich, Germany
| | - E Öz
- Max Planck Institute for Physics, 80805 Munich, Germany
| | | | - C Mutin
- CERN, 1211 Geneva, Switzerland
| | | | | | - F Peña Asmus
- Max Planck Institute for Physics, 80805 Munich, Germany
- Technical University Munich, 80333 Munich, Germany
| | | | - A Perera
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
- University of Liverpool, L69 7ZE Liverpool, United Kingdom
| | - A Petrenko
- CERN, 1211 Geneva, Switzerland
- Budker Institute of Nuclear Physics SB RAS, 630090 Novosibirsk, Russia
| | - S Pitman
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
- Lancaster University, LA1 4YB Lancaster, United Kingdom
| | - G Plyushchev
- CERN, 1211 Geneva, Switzerland
- Swiss Plasma Center, EPFL, 1015 Lausanne, Switzerland
| | - A Pukhov
- Heinrich-Heine-University of Düsseldorf, 40225 Düsseldorf, Germany
| | - S Rey
- CERN, 1211 Geneva, Switzerland
| | - K Rieger
- Max Planck Institute for Physics, 80805 Munich, Germany
| | - H Ruhl
- Ludwig-Maximilians-Universität, 80539 Munich, Germany
| | | | - I A Shalimova
- Novosibirsk State University, 630090 Novosibirsk, Russia
- Institute of Computational Mathematics and Mathematical Geophysics SB RAS, 630090 Novosibirsk, Russia
| | | | | | - L O Silva
- GoLP/Instituto de Plasmas e Fusão Nuclear, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisbon, Portugal
| | - L Soby
- CERN, 1211 Geneva, Switzerland
| | - A P Sosedkin
- Budker Institute of Nuclear Physics SB RAS, 630090 Novosibirsk, Russia
- Novosibirsk State University, 630090 Novosibirsk, Russia
| | | | - R I Spitsyn
- Budker Institute of Nuclear Physics SB RAS, 630090 Novosibirsk, Russia
- Novosibirsk State University, 630090 Novosibirsk, Russia
| | - P V Tuev
- Budker Institute of Nuclear Physics SB RAS, 630090 Novosibirsk, Russia
- Novosibirsk State University, 630090 Novosibirsk, Russia
| | | | - L Verra
- CERN, 1211 Geneva, Switzerland
- University of Milan, 20122 Milan, Italy
| | | | - J Vieira
- GoLP/Instituto de Plasmas e Fusão Nuclear, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisbon, Portugal
| | | | - C P Welsch
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
- University of Liverpool, L69 7ZE Liverpool, United Kingdom
| | - B Williamson
- University of Manchester, M13 9PL Manchester, United Kingdom
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
| | - M Wing
- UCL, WC1E 6BT London, United Kingdom
| | | | - G Xia
- University of Manchester, M13 9PL Manchester, United Kingdom
- Cockcroft Institute, WA4 4AD Daresbury, United Kingdom
| |
Collapse
|
16
|
Claassen Y, Bastiaannet E, Hartgrink H, Dikken J, De Steur W, Slingerland M, Verhoeven R, Van Eycken E, De Schutter H, Lindblad M, Hedberg J, Johnson E, Hjortland G, Jensen L, Larsson H, Koessler T, Chevallay M, Allum W, Van de Velde C. International comparison of treatment strategy and survival in metastatic gastric cancer: a survey from the EURECCA Upper GI group. Eur J Surg Oncol 2019. [DOI: 10.1016/j.ejso.2018.10.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
17
|
Gilmore-Bykovski A, Dhein J, Khloe I, Megan M, Block L, Jensen L. AN INPATIENT APPROACH TO SYMPTOM MANAGEMENT FOR PERSONS WITH DEMENTIA: THE PROACTIVE TREATMENT PROTOCOL. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- A Gilmore-Bykovski
- University of Wisconsin-Madison School of Nursing, Madison, Wisconsin, United States
| | - J Dhein
- William S. Middleton Memorial Veterans Hospital, Madison, WI, USA
| | - I Khloe
- William S. Middleton Memorial Veterans Hospital, Madison, WI, USA
| | - M Megan
- William S. Middleton Memorial Veterans Hospital, Madison, WI, USA
| | - L Block
- University of Wisconsin – Madison School of Nursing, Madison, WI, USA
| | - L Jensen
- William S. Middleton Memorial Veterans Hospital, Madison, WI, USA
| |
Collapse
|
18
|
Adli E, Ahuja A, Apsimon O, Apsimon R, Bachmann AM, Barrientos D, Batsch F, Bauche J, Berglyd Olsen VK, Bernardini M, Bohl T, Bracco C, Braunmüller F, Burt G, Buttenschön B, Caldwell A, Cascella M, Chappell J, Chevallay E, Chung M, Cooke D, Damerau H, Deacon L, Deubner LH, Dexter A, Doebert S, Farmer J, Fedosseev VN, Fiorito R, Fonseca RA, Friebel F, Garolfi L, Gessner S, Gorgisyan I, Gorn AA, Granados E, Grulke O, Gschwendtner E, Hansen J, Helm A, Henderson JR, Hüther M, Ibison M, Jensen L, Jolly S, Keeble F, Kim SY, Kraus F, Li Y, Liu S, Lopes N, Lotov KV, Maricalva Brun L, Martyanov M, Mazzoni S, Medina Godoy D, Minakov VA, Mitchell J, Molendijk JC, Moody JT, Moreira M, Muggli P, Öz E, Pasquino C, Pardons A, Peña Asmus F, Pepitone K, Perera A, Petrenko A, Pitman S, Pukhov A, Rey S, Rieger K, Ruhl H, Schmidt JS, Shalimova IA, Sherwood P, Silva LO, Soby L, Sosedkin AP, Speroni R, Spitsyn RI, Tuev PV, Turner M, Velotti F, Verra L, Verzilov VA, Vieira J, Welsch CP, Williamson B, Wing M, Woolley B, Xia G. Acceleration of electrons in the plasma wakefield of a proton bunch. Nature 2018; 561:363-367. [PMID: 30188496 PMCID: PMC6786972 DOI: 10.1038/s41586-018-0485-4] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2018] [Accepted: 08/14/2018] [Indexed: 12/03/2022]
Abstract
High-energy particle accelerators have been crucial in providing a deeper understanding of fundamental particles and the forces that govern their interactions. To increase the energy of the particles or to reduce the size of the accelerator, new acceleration schemes need to be developed. Plasma wakefield acceleration1–5, in which the electrons in a plasma are excited, leading to strong electric fields (so called ‘wakefields’), is one such promising acceleration technique. Experiments have shown that an intense laser pulse6–9 or electron bunch10,11 traversing a plasma can drive electric fields of tens of gigavolts per metre and above—well beyond those achieved in conventional radio-frequency accelerators (about 0.1 gigavolt per metre). However, the low stored energy of laser pulses and electron bunches means that multiple acceleration stages are needed to reach very high particle energies5,12. The use of proton bunches is compelling because they have the potential to drive wakefields and to accelerate electrons to high energy in a single acceleration stage13. Long, thin proton bunches can be used because they undergo a process called self-modulation14–16, a particle–plasma interaction that splits the bunch longitudinally into a series of high-density microbunches, which then act resonantly to create large wakefields. The Advanced Wakefield (AWAKE) experiment at CERN17–19 uses high-intensity proton bunches—in which each proton has an energy of 400 gigaelectronvolts, resulting in a total bunch energy of 19 kilojoules—to drive a wakefield in a ten-metre-long plasma. Electron bunches are then injected into this wakefield. Here we present measurements of electrons accelerated up to two gigaelectronvolts at the AWAKE experiment, in a demonstration of proton-driven plasma wakefield acceleration. Measurements were conducted under various plasma conditions and the acceleration was found to be consistent and reliable. The potential for this scheme to produce very high-energy electron bunches in a single accelerating stage20 means that our results are an important step towards the development of future high-energy particle accelerators21,22. Electron acceleration to very high energies is achieved in a single step by injecting electrons into a ‘wake’ of charge created in a 10-metre-long plasma by speeding long proton bunches.
Collapse
Affiliation(s)
- E Adli
- University of Oslo, Oslo, Norway
| | | | - O Apsimon
- University of Manchester, Manchester, UK.,Cockcroft Institute, Daresbury, UK
| | - R Apsimon
- Cockcroft Institute, Daresbury, UK.,Lancaster University, Lancaster, UK
| | - A-M Bachmann
- CERN, Geneva, Switzerland.,Max Planck Institute for Physics, Munich, Germany.,Technical University Munich, Munich, Germany
| | | | - F Batsch
- CERN, Geneva, Switzerland.,Max Planck Institute for Physics, Munich, Germany.,Technical University Munich, Munich, Germany
| | | | | | | | - T Bohl
- CERN, Geneva, Switzerland
| | | | | | - G Burt
- Cockcroft Institute, Daresbury, UK.,Lancaster University, Lancaster, UK
| | - B Buttenschön
- Max Planck Institute for Plasma Physics, Greifswald, Germany
| | - A Caldwell
- Max Planck Institute for Physics, Munich, Germany
| | | | | | | | | | | | | | | | - L H Deubner
- Philipps-Universität Marburg, Marburg, Germany
| | - A Dexter
- Cockcroft Institute, Daresbury, UK.,Lancaster University, Lancaster, UK
| | | | - J Farmer
- Heinrich-Heine-University of Düsseldorf, Düsseldorf, Germany
| | | | - R Fiorito
- Cockcroft Institute, Daresbury, UK.,University of Liverpool, Liverpool, UK
| | - R A Fonseca
- ISCTE-Instituto Universitéario de Lisboa, Lisbon, Portugal
| | | | | | | | | | - A A Gorn
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk, Russia.,Novosibirsk State University, Novosibirsk, Russia
| | | | - O Grulke
- Max Planck Institute for Plasma Physics, Greifswald, Germany.,Technical University of Denmark, Lyngby, Denmark
| | | | | | - A Helm
- GoLP/Instituto de Plasmas e Fusão Nuclear, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal
| | - J R Henderson
- Cockcroft Institute, Daresbury, UK.,Lancaster University, Lancaster, UK
| | - M Hüther
- Max Planck Institute for Physics, Munich, Germany
| | - M Ibison
- Cockcroft Institute, Daresbury, UK.,University of Liverpool, Liverpool, UK
| | | | | | | | | | - F Kraus
- Philipps-Universität Marburg, Marburg, Germany
| | - Y Li
- University of Manchester, Manchester, UK.,Cockcroft Institute, Daresbury, UK
| | - S Liu
- TRIUMF, Vancouver, British Columbia, Canada
| | - N Lopes
- GoLP/Instituto de Plasmas e Fusão Nuclear, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal
| | - K V Lotov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk, Russia.,Novosibirsk State University, Novosibirsk, Russia
| | | | - M Martyanov
- Max Planck Institute for Physics, Munich, Germany
| | | | | | - V A Minakov
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk, Russia.,Novosibirsk State University, Novosibirsk, Russia
| | - J Mitchell
- Cockcroft Institute, Daresbury, UK.,Lancaster University, Lancaster, UK
| | | | - J T Moody
- Max Planck Institute for Physics, Munich, Germany
| | - M Moreira
- CERN, Geneva, Switzerland.,GoLP/Instituto de Plasmas e Fusão Nuclear, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal
| | - P Muggli
- CERN, Geneva, Switzerland.,Max Planck Institute for Physics, Munich, Germany
| | - E Öz
- Max Planck Institute for Physics, Munich, Germany
| | | | | | - F Peña Asmus
- Max Planck Institute for Physics, Munich, Germany.,Technical University Munich, Munich, Germany
| | | | - A Perera
- Cockcroft Institute, Daresbury, UK.,University of Liverpool, Liverpool, UK
| | - A Petrenko
- CERN, Geneva, Switzerland.,Budker Institute of Nuclear Physics SB RAS, Novosibirsk, Russia
| | - S Pitman
- Cockcroft Institute, Daresbury, UK.,Lancaster University, Lancaster, UK
| | - A Pukhov
- Heinrich-Heine-University of Düsseldorf, Düsseldorf, Germany
| | - S Rey
- CERN, Geneva, Switzerland
| | - K Rieger
- Max Planck Institute for Physics, Munich, Germany
| | - H Ruhl
- Ludwig-Maximilians-Universität, Munich, Germany
| | | | - I A Shalimova
- Novosibirsk State University, Novosibirsk, Russia.,Institute of Computational Mathematics and Mathematical Geophysics SB RAS, Novosibirsk, Russia
| | | | - L O Silva
- GoLP/Instituto de Plasmas e Fusão Nuclear, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal
| | - L Soby
- CERN, Geneva, Switzerland
| | - A P Sosedkin
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk, Russia.,Novosibirsk State University, Novosibirsk, Russia
| | | | - R I Spitsyn
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk, Russia.,Novosibirsk State University, Novosibirsk, Russia
| | - P V Tuev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk, Russia.,Novosibirsk State University, Novosibirsk, Russia
| | | | | | - L Verra
- CERN, Geneva, Switzerland.,University of Milan, Milan, Italy
| | | | - J Vieira
- GoLP/Instituto de Plasmas e Fusão Nuclear, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal
| | - C P Welsch
- Cockcroft Institute, Daresbury, UK.,University of Liverpool, Liverpool, UK
| | - B Williamson
- University of Manchester, Manchester, UK.,Cockcroft Institute, Daresbury, UK
| | | | | | - G Xia
- University of Manchester, Manchester, UK.,Cockcroft Institute, Daresbury, UK
| |
Collapse
|
19
|
Smith J, Irwin A, Jensen L, Tedesco K, Misir S, Zhu W, Almonte A, He Y, Olivo M, O'Shaughnessy J. Abstract P6-14-05: Phase 2 study evaluating the efficacy and safety of eribulin mesylate administered biweekly for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-14-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Eribulin mesylate, a microtubule inhibitor, is approved in the US for the treatment of patients (pts) with metastatic breast cancer (MBC) who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease, including an anthracycline and a taxane. The recommended dose is 1.4 mg/m2 (equivalent to 1.23 mg/m2 eribulin [expressed as free base]) on day (D) 1 and D8 of a 21-D cycle. However, this schedule can result in dose delays and reductions due to myelosuppression. A dosing regimen of eribulin (1.4 mg/m2) administered intravenously (IV) biweekly (Q2W; on D1 and D15) in 28-D cycles was evaluated with the intent of improving eribulin's safety profile without compromising efficacy.
Methods: Female pts with human epidermal growth factor receptor (HER)2-negative MBC, who had received 2-5 prior chemotherapy regimens and had ECOG PS ≤2 were enrolled in 12 sites in the US. Prophylactic granulocyte colony-stimulating factor (G-CSF) was not allowed. If neutropenia occurred, growth factors were used during eribulin treatment at the physician's discretion. Primary endpoints were objective response rate (ORR) and disease control rate (DCR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), dose intensity (measured by feasibility rate), safety and tolerability.
Results: Median age of the 58 enrolled pts was 64 yrs (range: 38-85). The majority of pts (93%) had ECOG PS ≤1, and 12% of pts had triple-negative MBC. Number of prior chemotherapeutic regimens: 2 (17% of patients), 3 (24%), 4 (27%), and 5 (31%). 76% Of pts had visceral disease and 86% had previous taxane therapy. ORR (95% confidence interval [CI]) was 12% (5-24), DCR (CR+PR+SD) was 65% (95% CI: 51-77), and CBR (CR+PR+SD ≥23 weeks) was 30% (95% CI: 18-43) [n=57]. Median PFS (95% CI) was 3.6 mo (2.9-4.1). Median OS (95% CI) was 13.2 mo (10.6-not estimable). 6-Month and 12-month OS rates were 84% and 54%, respectively. Dose intensity measured by the feasibility rate (defined as the percentage of pts completing the first 2 and 4 cycles without a dose delay >5 days or dose reduction due to an adverse event [AE]) was 70% and 46%, respectively.
The most frequent AEs (all grades) were neutropenia (69%), fatigue (48%), alopecia (45%), and constipation (36%). 22% Of pts had grade (G) 1 alopecia and 22% of pts had G2 alopecia. 72% Of pts had G3/4 AEs: neutropenia, 57%, and peripheral neuropathy, 12%. G3 peripheral sensory neuropathy occurred in 9% of pts, with no G4 incidence. There were 2 deaths (1 sepsis, 1 acute respiratory failure), which were considered not related to treatment. 50% (29/58) Of all patients received at least 1 dose of growth factor and 70% (28/40) of patients with neutropenia received growth-factor support.
Conclusions: Tumor response rates and OS of this treatment schedule in a heavily pretreated patient population were similar compared to previously reported phase 3 studies of eribulin. The toxicities associated with biweekly eribulin were manageable.
Citation Format: Smith II J, Irwin A, Jensen L, Tedesco K, Misir S, Zhu W, Almonte A, He Y, Olivo M, O'Shaughnessy J. Phase 2 study evaluating the efficacy and safety of eribulin mesylate administered biweekly for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-14-05.
Collapse
Affiliation(s)
- J Smith
- Compass Oncology, Portland, OR; US Oncology, The Woodlands, TX; Virginia Cancer Specialists, Leesburg, VA; Rocky Mountain Cancer Centers, Boulder, CO; New York Oncology Hematology, Albany, NY; Eisai Inc., Woodcliff Lake, NJ; Baylor University Medical Center, Texas Oncology, Dallas, TX
| | - A Irwin
- Compass Oncology, Portland, OR; US Oncology, The Woodlands, TX; Virginia Cancer Specialists, Leesburg, VA; Rocky Mountain Cancer Centers, Boulder, CO; New York Oncology Hematology, Albany, NY; Eisai Inc., Woodcliff Lake, NJ; Baylor University Medical Center, Texas Oncology, Dallas, TX
| | - L Jensen
- Compass Oncology, Portland, OR; US Oncology, The Woodlands, TX; Virginia Cancer Specialists, Leesburg, VA; Rocky Mountain Cancer Centers, Boulder, CO; New York Oncology Hematology, Albany, NY; Eisai Inc., Woodcliff Lake, NJ; Baylor University Medical Center, Texas Oncology, Dallas, TX
| | - K Tedesco
- Compass Oncology, Portland, OR; US Oncology, The Woodlands, TX; Virginia Cancer Specialists, Leesburg, VA; Rocky Mountain Cancer Centers, Boulder, CO; New York Oncology Hematology, Albany, NY; Eisai Inc., Woodcliff Lake, NJ; Baylor University Medical Center, Texas Oncology, Dallas, TX
| | - S Misir
- Compass Oncology, Portland, OR; US Oncology, The Woodlands, TX; Virginia Cancer Specialists, Leesburg, VA; Rocky Mountain Cancer Centers, Boulder, CO; New York Oncology Hematology, Albany, NY; Eisai Inc., Woodcliff Lake, NJ; Baylor University Medical Center, Texas Oncology, Dallas, TX
| | - W Zhu
- Compass Oncology, Portland, OR; US Oncology, The Woodlands, TX; Virginia Cancer Specialists, Leesburg, VA; Rocky Mountain Cancer Centers, Boulder, CO; New York Oncology Hematology, Albany, NY; Eisai Inc., Woodcliff Lake, NJ; Baylor University Medical Center, Texas Oncology, Dallas, TX
| | - A Almonte
- Compass Oncology, Portland, OR; US Oncology, The Woodlands, TX; Virginia Cancer Specialists, Leesburg, VA; Rocky Mountain Cancer Centers, Boulder, CO; New York Oncology Hematology, Albany, NY; Eisai Inc., Woodcliff Lake, NJ; Baylor University Medical Center, Texas Oncology, Dallas, TX
| | - Y He
- Compass Oncology, Portland, OR; US Oncology, The Woodlands, TX; Virginia Cancer Specialists, Leesburg, VA; Rocky Mountain Cancer Centers, Boulder, CO; New York Oncology Hematology, Albany, NY; Eisai Inc., Woodcliff Lake, NJ; Baylor University Medical Center, Texas Oncology, Dallas, TX
| | - M Olivo
- Compass Oncology, Portland, OR; US Oncology, The Woodlands, TX; Virginia Cancer Specialists, Leesburg, VA; Rocky Mountain Cancer Centers, Boulder, CO; New York Oncology Hematology, Albany, NY; Eisai Inc., Woodcliff Lake, NJ; Baylor University Medical Center, Texas Oncology, Dallas, TX
| | - J O'Shaughnessy
- Compass Oncology, Portland, OR; US Oncology, The Woodlands, TX; Virginia Cancer Specialists, Leesburg, VA; Rocky Mountain Cancer Centers, Boulder, CO; New York Oncology Hematology, Albany, NY; Eisai Inc., Woodcliff Lake, NJ; Baylor University Medical Center, Texas Oncology, Dallas, TX
| |
Collapse
|
20
|
Jensen L, Overgaard C, Bøggild H, Garne JP, Lund T, Overvad K, Fonager K. The Long-term financial consequences of breast cancer: a Danish registry-based cohort study. Eur J Public Health 2017. [DOI: 10.1093/eurpub/ckx187.690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- L Jensen
- Department of Social Medicine, Aalborg University Hospital, Aalborg, Denmark
| | - C Overgaard
- Department of Social Medicine, Aalborg University Hospital, Aalborg, Denmark
| | - H Bøggild
- Department of Epidemiology and Biostatistics, Aalborg University Hospital, Aalborg, Denmark
| | - JP Garne
- Department of Breast surgery, Aalborg University Hospital, Aalborg, Denmark
| | - T Lund
- Department of Public Health and Quality Improvement, Aarhus, Central Denmark Region, Aarhus, Denmark
| | - K Overvad
- Department of Public Health – Section for Epidemiology, Aarhus University, Aarhus, Denmark
| | - K Fonager
- Department of Social Medicine, Aalborg University Hospital, Aalborg, Denmark
| |
Collapse
|
21
|
Blech-Hermoni Y, Coscia S, Jensen L, Kates M, Subedi K, Mankodi A. Expression of myofibrillar myopathy gene products in the nervous system. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
22
|
Jensen L, Petersson S, Illum N, Laugaard-Jacobsen H, Thelle T, Jørgensen L, Schrøder H. Muscular response to the first three months of deflazacort treatment in boys with Duchenne muscular dystrophy. J Musculoskelet Neuronal Interact 2017; 17:8-18. [PMID: 28574407 PMCID: PMC5492315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
OBJECTIVE Duchenne muscular dystrophy (DMD) patients are often treated with glucocorticoids; yet their precise molecular action remains unknown. METHODS We investigated muscle biopsies from nine boys with DMD (aged: 7,6±2,8 yrs.) collected before and after three months of deflazacort treatment and compared them to eight healthy boys (aged: 5,3±2,4 yrs.). mRNA transcripts involved in activation of satellite cells, myogenesis, regeneration, adipogenesis, muscle growth and tissue inflammation were assessed. Serum creatine kinase (CK) levels and muscle protein expression by immunohistochemistry of selected targets were also analysed. RESULTS Transcript levels for ADIPOQ, CD68, CDH15, FGF2, IGF1R, MYF5, MYF6, MYH8, MYOD, PAX7, and TNFα were significantly different in untreated patients vs. normal muscle (p⟨0.05). Linear tests for trend indicated that the expression levels of treated patients were approaching normal values (p⟨0.05) following treatment (towards an increase; CDH15, C-MET, DLK1, FGF2, IGF1R, MYF5, MYF6, MYOD, PAX7; towards a decrease: CD68, MYH8, TNFα). Treatment reduced CK levels (p⟨0.05), but we observed no effect on muscle protein expression. CONCLUSIONS This study provides insight into the molecular actions of glucocorticoids in DMD at the mRNA level, and we show that multiple regulatory pathways are influenced. This information can be important in the development of new treatments.
Collapse
Affiliation(s)
- L. Jensen
- Department of Clinical Pathology, Institute of Clinical Research, University of Southern Denmark and Odense University Hospital, 5000 Odense C, Denmark
| | - S.J. Petersson
- Department of Clinical Pathology, Institute of Clinical Research, University of Southern Denmark and Odense University Hospital, 5000 Odense C, Denmark
| | - N.O. Illum
- H.C. Andersen Children’s Hospital, Odense University Hospital, 5000 Odense C, Denmark
| | | | - T. Thelle
- Pediatric Department, Regional Hospital Central Jutland, 8800 Viborg, Denmark
| | - L.H. Jørgensen
- Department of Clinical Pathology, Institute of Clinical Research, University of Southern Denmark and Odense University Hospital, 5000 Odense C, Denmark
| | - H.D. Schrøder
- Department of Clinical Pathology, Institute of Clinical Research, University of Southern Denmark and Odense University Hospital, 5000 Odense C, Denmark,Corresponding author: Henrik Daa Schrøder, Institute of Clinical Research, Clinical Pathology, Odense University Hospital, JB. Winsløw Vej 15, 2. DK-5000 Odense C, Denmark E-mail:
| |
Collapse
|
23
|
Kjaer TR, Jensen L, Hansen A, Dani R, Jensenius JC, Dobó J, Gál P, Thiel S. Oligomerization of Mannan-binding Lectin Dictates Binding Properties and Complement Activation. Scand J Immunol 2017; 84:12-9. [PMID: 27104295 DOI: 10.1111/sji.12441] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2016] [Accepted: 04/13/2016] [Indexed: 01/13/2023]
Abstract
The complement system is a part of the innate immune system and is involved in recognition and clearance of pathogens and altered-self structures. The lectin pathway of the complement system is initiated when soluble pattern recognition molecules (PRMs) with collagen-like regions bind to foreign or altered self-surfaces. Associated with the collagen-like stems of these PRMs are three mannan-binding lectin (MBL)-associated serine proteases (MASPs) and two MBL-associated proteins (MAps). The most studied of the PRMs, MBL, is present in serum mainly as trimeric and tetrameric oligomers of the structural subunit. We hypothesized that oligomerization of MBL may influence both the potential to bind to micro organisms and the interaction with the MASPs and MAps, thus influencing the ability to initiate complement activation. When testing binding at 37 °C, we found higher binding of tetrameric MBL to Staphylococcus aureus (S. aureus) than trimeric and dimeric MBL. In serum, we found that tetrameric MBL was the main oligomeric form present in complexes with the MASPs and MAp44. Such preference was confirmed using purified forms of recombinant MBL (rMBL) oligomers, where tetrameric rMBL interacted stronger with all of the MASPs and MAp44, compared to trimeric MBL. As a direct consequence of the weaker interaction with the MASPs, we found that trimeric rMBL was inferior to tetrameric rMBL in activating the complement system. Our data suggest that the oligomeric state of MBL is crucial both for the binding properties and the effector function of MBL.
Collapse
Affiliation(s)
- T R Kjaer
- Department of Biomedicine, Aarhus University, Aarhus, Denmark
| | - L Jensen
- Department of Biomedicine, Aarhus University, Aarhus, Denmark
| | - A Hansen
- Department of Biomedicine, Aarhus University, Aarhus, Denmark
| | - R Dani
- Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary
| | - J C Jensenius
- Department of Biomedicine, Aarhus University, Aarhus, Denmark
| | - J Dobó
- Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary
| | - P Gál
- Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary
| | - S Thiel
- Department of Biomedicine, Aarhus University, Aarhus, Denmark
| |
Collapse
|
24
|
Lagali N, Mukwaya A, Mirabelli P, Jensen L, Xeroudaki M, Ali Z, Peebo B. Identifying VEGF-independent factors for targeted antiangiogenic therapy in the cornea. Acta Ophthalmol 2016. [DOI: 10.1111/j.1755-3768.2016.0036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
25
|
Folsom S, Schoenhals S, Jensen L, Fassl B, Dickerson T. Novel approach to engage medical students in global health education and
application. Ann Glob Health 2016. [DOI: 10.1016/j.aogh.2016.04.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
26
|
|
27
|
|
28
|
Green M, Haigh SJ, Lewis EA, Sandiford L, Burkitt-Gray M, Fleck R, Vizcay-Barrena G, Jensen L, Mirzai H, Curry RJ, Dailey LA. Erratum: The Biosynthesis of Infrared-Emitting Quantum Dots in Allium Fistulosum. Sci Rep 2016; 6:22497. [PMID: 26940776 PMCID: PMC4778373 DOI: 10.1038/srep22497] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Green M, Haigh SJ, Lewis EA, Sandiford L, Burkitt-Gray M, Fleck R, Vizcay-Barrena G, Jensen L, Mirzai H, Curry RJ, Dailey LA. The Biosynthesis of Infrared-Emitting Quantum Dots in Allium Fistulosum. Sci Rep 2016; 6:20480. [PMID: 26857581 PMCID: PMC4746658 DOI: 10.1038/srep20480] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2015] [Accepted: 01/04/2016] [Indexed: 11/24/2022] Open
Abstract
The development of simple routes to emissive solid-state materials is of paramount interest, and in this report we describe the biosynthesis of infrared emitting quantum dots in a living plant via a mutual antagonistic reaction. Exposure of common Allium fistulosum to mercury and tellurium salts under ambient conditions resulted in the expulsion of crystalline, non-passivated HgTe quantum dots that exhibited emissive characteristics in the near-infrared spectral region, a wavelength range that is important in telecommunications and solar energy conversion.
Collapse
Affiliation(s)
- M Green
- Department of Physics, King's College London, The Strand, London WC2R 2LS, UK
| | - S J Haigh
- School of Materials, The University of Manchester, Manchester, M13 9PL, UK
| | - E A Lewis
- School of Materials, The University of Manchester, Manchester, M13 9PL, UK
| | - L Sandiford
- Department of Physics, King's College London, The Strand, London WC2R 2LS, UK.,Department of Imaging Chemistry and Biology, Divisions of Imaging Science and Biomedical Engineering, King's College London, 4th floor, Lambert Wing, St Thomas' Hospital, London SE1 7EH, UK
| | - M Burkitt-Gray
- Department of Physics, King's College London, The Strand, London WC2R 2LS, UK.,The Centre for Ultrastructural Imaging, King's College London, New Hunt's House, London SE1 1UL. UK
| | - R Fleck
- The Centre for Ultrastructural Imaging, King's College London, New Hunt's House, London SE1 1UL. UK
| | - G Vizcay-Barrena
- The Centre for Ultrastructural Imaging, King's College London, New Hunt's House, London SE1 1UL. UK
| | - L Jensen
- The Centre for Ultrastructural Imaging, King's College London, New Hunt's House, London SE1 1UL. UK
| | - H Mirzai
- Department of Physics, King's College London, The Strand, London WC2R 2LS, UK
| | - R J Curry
- Advanced Technology Institute, Department of Electronic Engineering, University of Surrey, Guildford, Surrey GU2 7XH, UK
| | - L-A Dailey
- Institute of Pharmaceutical Science,, King's College London, 5th Floor, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, UK
| |
Collapse
|
30
|
Holmgaard R, Duffy J, Warburg FE, Jensen L, Bonde C. Danish experience with free flaps in war wounds. Dan Med J 2016; 63:A5180. [PMID: 26726898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
INTRODUCTION To describe the lessons learned from treatment of war casualties at a public hospital in Denmark. METHODS A retrospective review of soldiers who underwent free flap reconstruction at Rigshospitalet, Denmark, between January 2006 and December 2010. RESULTS Nine patients were treated using free flaps. The age distribution was 21-34 years. Extremity fractures associated with considerable soft tissue loss were seen in all cases. The mean time from injury to reconstruction was 13.2 days. A total of 11 free flaps were used, the majority of which were latissimus dorsi flaps (seven out of 11). Flap-loss occurred in one patient, presumably due to leakage at the anastomotic site, which necessitated another free flap procedure. All patients received rehabilitation services following discharge from the inpatient unit, including prosthetic fitting. The mean follow-up time was 26 months. CONCLUSIONS This report is the first to detail the reconstructive procedures in soldiers treated at a public hospital in Denmark. The treatment of war casualties has not only been a challenge to the surgeons tasked with managing these devastating injuries, but also to Danish healthcare in general. The outcome of multidisciplinary treatment, combining the expertise of various specialties, is highly encouraging. The rate of complications was low, and the aesthetic appearance of the reconstructed limbs and the functional recovery were satisfactory. We therefore recommend the use of free flaps to reconstruct defects resulting from battlefield trauma. FUNDING none. TRIAL REGISTRATION not relevant.
Collapse
|
31
|
Bridgewater J, Lopes A, Wasan H, Malka D, Jensen L, Okusaka T, Knox J, Wagner D, Cunningham D, Shannon J, Goldstein D, Moehler M, Bekaii-Saab T, McNamara M, Valle J. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann Oncol 2016; 27:134-140. [DOI: 10.1093/annonc/mdv483] [Citation(s) in RCA: 76] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
32
|
Troldborg A, Thiel S, Jensen L, Hansen S, Laska MJ, Deleuran B, Jensenius JC, Stengaard-Pedersen K. Collectin liver 1 and collectin kidney 1 and other complement-associated pattern recognition molecules in systemic lupus erythematosus. Clin Exp Immunol 2015; 182:132-8. [PMID: 26154564 PMCID: PMC4608502 DOI: 10.1111/cei.12678] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2015] [Revised: 07/02/2015] [Accepted: 07/03/2015] [Indexed: 11/30/2022] Open
Abstract
The objective of this study was to explore the involvement of collectin liver 1 (CL-L1) and collectin kidney 1 (CL-K1) and other pattern recognition molecules (PRMs) of the lectin pathway of the complement system in a cross-sectional cohort of systemic lupus erythematosus (SLE) patients. Concentrations in plasma of CL-L1, CL-K1, mannan-binding lectin (MBL), M-ficolin, H-ficolin and L-ficolin were determined in 58 patients with SLE and 65 healthy controls using time-resolved immunoflourometric assays. The SLE patients' demographic, diagnostic, clinical and biochemical data and collection of plasma samples were performed prospectively during 4 months. CL-L1, CL-K1 and M-ficolin plasma concentrations were lower in SLE patients than healthy controls (P-values < 0.001, 0.033 and < 0.001, respectively). H-ficolin concentration was higher in SLE patients (P < 0.0001). CL-L1 and CL-K1 plasma concentrations in the individuals correlated in both patients and controls. Patients with low complement component 3 (C3) demonstrated a negative correlation between C3 and CL-L1 and CL-K1 (P = 0.022 and 0.031, respectively). Patients positive for anti-dsDNA antibodies had lower levels of MBL in plasma than patients negative for anti-dsDNA antibodies (P = 0.02). In a cross-sectional cohort of SLE patients, we found differences in the plasma concentrations of CL-L1, CL-K1, M-ficolin and H-ficolin compared to a group of healthy controls. Alterations in plasma concentrations of the PRMs of the lectin pathway in SLE patients and associations to key elements of the disease support the hypothesis that the lectin pathway plays a role in the pathogenesis of SLE.
Collapse
Affiliation(s)
- A Troldborg
- Center of Cancer and InflammationDepartment of Rheumatology, Aarhus University Hospital, Aarhus University
- Institute of Clinical Medicine, Aarhus University
| | - S Thiel
- Department of Biomedicine, Aarhus University
| | - L Jensen
- Department of Biomedicine, Aarhus University
| | - S Hansen
- Department of Cancer and Inflammation Research, University of Southern Denmark
| | - M J Laska
- Department of Biomedicine, Aarhus University
| | - B Deleuran
- Center of Cancer and InflammationDepartment of Rheumatology, Aarhus University Hospital, Aarhus University
- Department of Biomedicine, Aarhus University
| | | | - K Stengaard-Pedersen
- Center of Cancer and InflammationDepartment of Rheumatology, Aarhus University Hospital, Aarhus University
- Institute of Clinical Medicine, Aarhus University
| |
Collapse
|
33
|
Pieber TR, Deller S, Korsatko S, Jensen L, Christiansen E, Madsen J, Heller SR. Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial. Diabetes Obes Metab 2015; 17:742-50. [PMID: 25855340 DOI: 10.1111/dom.12473] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2014] [Revised: 03/20/2015] [Accepted: 04/03/2015] [Indexed: 12/25/2022]
Abstract
AIMS To investigate the effect of glucagon-like peptide 1 receptor agonist liraglutide on the counter-regulatory hormone response to hypoglycaemia in type 1 diabetes. METHODS We conducted a randomized, double-blind, placebo-controlled, single-centre trial, in which a total of 45 adults with type 1 diabetes [mean ± standard deviation age 34.5 ± 11.2 years, BMI 23.9 ± 2.4 kg/m(2) , glycated haemoglobin (HbA1c) 7.6 ± 0.8%, diabetes duration 16.6 ± 9.4 years] underwent a hypoglycaemic clamp after 4 weeks' crossover treatment with once-daily liraglutide/placebo added to insulin in one of three liraglutide dose groups: 0.6 mg (n = 15); 1.2 mg (n = 14); and 1.8 mg (n = 16). The main outcome measure was glucagon concentration at nadir plasma glucose (2.5 mmol/l). Clinical outcomes were also evaluated. Five participants were withdrawn from the trial; three because of adverse events. All participants were included in the analysis. RESULTS Glucagon concentration at nadir plasma glucose was modest, trending towards lower concentrations at increasing liraglutide dose versus placebo: 34.7 versus 38.1 pg/ml, p = 0.555 (0.6 mg); 28.8 versus 37.2 pg/ml, p = 0.126 (1.2 mg); and 28.4 versus 37.5 pg/ml, p = 0.092 (1.8 mg). There was no difference, however, between liraglutide and placebo in incremental change in glucagon during hypoglycaemia. Other counter-regulatory hormone levels increased during hypoglycaemia with no systematic differences between groups. Glucose infusion rates were significantly lower with liraglutide versus placebo during the clamp. After 4 weeks' treatment, HbA1c remained unchanged in the liraglutide and placebo groups. Greater reductions in insulin dose and body weight were seen with liraglutide versus placebo. CONCLUSIONS Liraglutide did not compromise hypoglycaemic responses in type 1 diabetes after 4 weeks' treatment.
Collapse
Affiliation(s)
- T R Pieber
- Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria
| | - S Deller
- Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria
| | - S Korsatko
- Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria
| | - L Jensen
- Novo Nordisk A/S, Søborg, Denmark
| | | | - J Madsen
- Novo Nordisk A/S, Søborg, Denmark
| | - S R Heller
- Academic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, UK
| |
Collapse
|
34
|
Straker L, Howie E, Smith A, Jensen L, Piek J, Campbell A. A crossover randomised and controlled trial of the impact of active video games on motor coordination and perceptions of physical ability in children at risk of Developmental Coordination Disorder. Hum Mov Sci 2015; 42:146-60. [PMID: 26037276 DOI: 10.1016/j.humov.2015.04.011] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2014] [Revised: 04/23/2015] [Accepted: 04/24/2015] [Indexed: 01/25/2023]
Abstract
BACKGROUND Impaired motor development can significantly affect a child's life and may result in an increased risk of a range of physical and psychological disorders. Active video game (AVG) interventions have been demonstrated to enhance motor skills in children with Developmental Coordination Disorder (DCD); however a home-based intervention has not been assessed. OBJECTIVES The primary aim of this study was to compare the changes in motor coordination between a 16 week period of AVG use, with 16 weeks of normal activities (NAG). The secondary aim was to compare the child and parent perceptions of their physical performance between the AVG and NAG conditions. METHODS Twenty-one 9-12 year olds (10 males) were confirmed to be at risk of DCD (⩽ 16th percentile Movement Assessment Battery for Children-2nd edition (MABC-2) and ⩽ 15th percentile Developmental Coordination Disorder Questionnaire (DCDQ)) and participated in this crossover randomised and controlled trial. Data was collected at study entry, after the first 16 week condition and following the final 16 week condition, including; (1) the MABC-2, (2) three-dimensional motion analysis of single leg balance and finger-nose tasks, and (3) parent perception of physical skills. Participant perception of physical skills was collected only after the first and second conditions. RESULTS There was no significant difference between AVG and NAG for any of the primary variables including the MABC-2, balance centre-of-mass path distance and finger-nose path distance. There was no significant intervention effect for secondary measures of motor coordination; however the children perceived their motor skills to be significantly enhanced as a result of the AVG intervention in comparison to the period of no intervention. CONCLUSION A 16 week home based AVG intervention did not enhance motor skills in children with DCD, although they perceived their physical skills to be significantly improved. TRIAL REGISTRATION Australia and New Zealand Clinical trials Registry (ACTRN 12611000400965).
Collapse
Affiliation(s)
- L Straker
- School of Physiotherapy and Exercise Science, Curtin University, Australia
| | - E Howie
- School of Physiotherapy and Exercise Science, Curtin University, Australia
| | - A Smith
- School of Physiotherapy and Exercise Science, Curtin University, Australia
| | - L Jensen
- School of Physiotherapy and Exercise Science, Curtin University, Australia
| | - J Piek
- School of Psychology & Speech Pathology, Curtin University, Australia
| | - A Campbell
- School of Physiotherapy and Exercise Science, Curtin University, Australia.
| |
Collapse
|
35
|
Gómez-Maldonado L, Tiana M, Roche O, Prado-Cabrero A, Jensen L, Fernandez-Barral A, Guijarro-Muñoz I, Favaro E, Moreno-Bueno G, Sanz L, Aragones J, Harris A, Volpert O, Jimenez B, del Peso L. EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination. Oncogene 2015; 34:2609-20. [PMID: 25023702 PMCID: PMC4722872 DOI: 10.1038/onc.2014.200] [Citation(s) in RCA: 81] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2013] [Revised: 05/09/2014] [Accepted: 05/09/2014] [Indexed: 01/04/2023]
Abstract
The presence of hypoxic regions in solid tumors is an adverse prognostic factor for patient outcome. Here, we show that hypoxia induces the expression of Ephrin-A3 through a novel hypoxia-inducible factor (HIF)-mediated mechanism. In response to hypoxia, the coding EFNA3 mRNA levels remained relatively stable, but HIFs drove the expression of previously unknown long noncoding (lnc) RNAs from EFNA3 locus and these lncRNA caused Ephrin-A3 protein accumulation. Ephrins are cell surface proteins that regulate diverse biological processes by modulating cellular adhesion and repulsion. Mounting evidence implicates deregulated ephrin function in multiple aspects of tumor biology. We demonstrate that sustained expression of both Ephrin-A3 and novel EFNA3 lncRNAs increased the metastatic potential of human breast cancer cells, possibly by increasing the ability of tumor cells to extravasate from the blood vessels into surrounding tissue. In agreement, we found a strong correlation between high EFNA3 expression and shorter metastasis-free survival in breast cancer patients. Taken together, our results suggest that hypoxia could contribute to metastatic spread of breast cancer via HIF-mediated induction of EFNA3 lncRNAs and subsequent Ephrin-A3 protein accumulation.
Collapse
Affiliation(s)
- L Gómez-Maldonado
- Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM) and Instituto de Investigaciones Biomédicas ‘Alberto Sols’ (CSIC-UAM), Madrid, Spain
| | - M Tiana
- Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM) and Instituto de Investigaciones Biomédicas ‘Alberto Sols’ (CSIC-UAM), Madrid, Spain
| | - O Roche
- Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM) and Instituto de Investigaciones Biomédicas ‘Alberto Sols’ (CSIC-UAM), Madrid, Spain
- IdiPaz, Instituto de Investigación Sanitaria del Hospital Universitario La Paz, Madrid, Spain
| | - A Prado-Cabrero
- Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM) and Instituto de Investigaciones Biomédicas ‘Alberto Sols’ (CSIC-UAM), Madrid, Spain
| | - L Jensen
- Department of Medicine and Health Sciences, Linköping University Linköping, Sweden
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden
| | - A Fernandez-Barral
- Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM) and Instituto de Investigaciones Biomédicas ‘Alberto Sols’ (CSIC-UAM), Madrid, Spain
| | - I Guijarro-Muñoz
- Molecular Immunology Unit, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
| | - E Favaro
- Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK
| | - G Moreno-Bueno
- Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM) and Instituto de Investigaciones Biomédicas ‘Alberto Sols’ (CSIC-UAM), Madrid, Spain
| | - L Sanz
- Molecular Immunology Unit, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
| | - J Aragones
- Research Unit, Hospital Universitario Santa Cristina, Research Institute Princesa, Autonomous University of Madrid, Madrid, Spain
| | - A Harris
- Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK
| | - O Volpert
- Urology Department, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - B Jimenez
- Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM) and Instituto de Investigaciones Biomédicas ‘Alberto Sols’ (CSIC-UAM), Madrid, Spain
| | - L del Peso
- Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM) and Instituto de Investigaciones Biomédicas ‘Alberto Sols’ (CSIC-UAM), Madrid, Spain
- IdiPaz, Instituto de Investigación Sanitaria del Hospital Universitario La Paz, Madrid, Spain
| |
Collapse
|
36
|
Stuart E, Jensen L, Downs J. Motor development and activity in toddlers who were born preterm. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.1412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
37
|
Jensen L, Piek J, Kane R, Downs J. Male infants and infants born small for gestational age are at risk of fine motor delay in infancy. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.3521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
38
|
Straker L, Campbell A, Howie E, Smith A, Piek J, Jensen L, Pollock C. Can active video games enhance motor coordination in children with developmental coordination disorder? Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.3523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
39
|
Villesen CT, Schmidt AMS, Jensen L, Herkell K, Iversen J, Andersen L, Nørregaard S, Elsner D. CP-053 Identification of a national portfolio of unlicensed pharmaceutical preparations in denmark. Eur J Hosp Pharm 2015. [DOI: 10.1136/ejhpharm-2015-000639.50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
40
|
Mitchell D, Venermo M, Mani K, Bjorck M, Troeng T, Debus S, Szeberin Z, Hansen A, Beiles B, Setacci C, Bergqvist D, Menyhei G, Heller G, Danielsson G, Loftus I, Thomson I, Vogt K, Jensen L, Altreuther M, Eldrup N, Wigger P, Moreno-Carriles R, Lees T. Quality Improvement in Vascular Surgery: The Role of Comparative Audit and Vascunet. Eur J Vasc Endovasc Surg 2015; 49:1-3. [DOI: 10.1016/j.ejvs.2014.08.026] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
41
|
Thomas J, Jensen L, Bainey K. DEPRESSIVE SYMPTOMS AND ASSOCIATED FACTORS IN AN OUTPATIENT CARDIOLOGY CLINIC COHORT. Can J Cardiol 2014. [DOI: 10.1016/j.cjca.2014.07.686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
42
|
Jensen L, Han C, Schultheiss T, Wong J, Sampath S. Higher Delivered Bowel Doses Due to Lower Bladder Volumes in Patients Receiving Postprostatectomy Salvage Radiation therapy. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
43
|
de Steur W, Henneman D, Allum W, Dikken J, van Sandick J, Reynolds J, Mariette C, Jensen L, Johansson J, Kolodziejczyk P, Hardwick R, van de Velde C. Common data items in seven European oesophagogastric cancer surgery registries: Towards a European Upper GI cancer audit (EURECCA Upper GI). Eur J Surg Oncol 2014; 40:325-9. [DOI: 10.1016/j.ejso.2013.11.021] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2013] [Accepted: 11/22/2013] [Indexed: 11/25/2022] Open
|
44
|
Al Kotbi N, Jensen L, Graff L. FRI0196 NNC0109-0012 (anti-IL-20 MAB), well tolerated in healthy subjects and patients with rheumatoid arthritis. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2012-eular.2653] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
45
|
Fisher RE, Jensen L, Adams KA. Abstract P3-08-08: Pattern of use of an online primary health care information resource for breast cancer survivorship education: The pink ribbon survivors network. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-08-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The Pink Ribbon Survivors Network, a 501(c)(3) nonprofit organization founded by cancer professionals, developed an online educational resource for breast cancer survivors, cancer care professionals, and primary health care providers. The organization created a separate online educational library for each of these three separate audiences. The organization's website launched in July, 2012.
Methods: The Primary Health Care Library for breast cancer survivorship education houses 15 unique categories. Utilizing the organization's administrative website, numerical pattern of access of each separate listing in the 15 categories can be obtained. In addition, Google Analytics data was utilized to determine total website activity for all three educational libraries.
Results: As of abstract submission, the Primary Healthcare Breast Cancer Survivorship Education Library contains 141 clinical articles in 15 categories. The website has been utilized in all 50 of the United States, and in 66 countries and 890 cities. The five most viewed categories of the 15 total categories are (in descending order): 1.) Lifestyle Modifications, 2.) Creating a Link between Cancer Care and Primary Care: Clinical Literature on Survivorship, 3.) Depression/Mood Disturbance, 4.) Consensus Panel Guidelines for Breast Cancer Follow up, and 5.) Gynecologic Issues: Sexuality/Fertility.
Conclusion: Since it's creation in mid- 2012, an online breast cancer survivorship resource is being utilized for educational review. Users of the website are preferentially interested in QOL, healthcare system, and Consensus guidance in their educational viewing. This system can be utilized to disseminate nationally recognized clinical advice for Primary Healthcare Providers as they care for breast cancer survivors in their routine healthcare practices.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-08-08.
Collapse
Affiliation(s)
- RE Fisher
- Rocky Mountain Cancer Centers, Boulder, CO; University of Colorado Cancer Center, Aurora, CO
| | - L Jensen
- Rocky Mountain Cancer Centers, Boulder, CO; University of Colorado Cancer Center, Aurora, CO
| | - KA Adams
- Rocky Mountain Cancer Centers, Boulder, CO; University of Colorado Cancer Center, Aurora, CO
| |
Collapse
|
46
|
Brinkmann C, Jensen L, Dagnaes-Hansen F, Holm I, Endo Y, Fujita T, Thiel S, Jensenius J, Degn S. Mitochondria and the lectin pathway of complement. Mol Immunol 2013. [DOI: 10.1016/j.molimm.2013.05.181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
47
|
Evans A, Geraughty S, Gaughen J, Jensen L, Wintermark M. E-017 Intracranial Stenting with Balloon Mounted Stents: Initial Safety and Long Term Follow up. J Neurointerv Surg 2013. [DOI: 10.1136/neurintsurg-2013-010870.75] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
48
|
Suetta C, Frandsen U, Mackey AL, Jensen L, Hvid LG, Bayer ML, Petersson SJ, Schrøder HD, Andersen JL, Aagaard P, Schjerling P, Kjaer M. Ageing is associated with diminished muscle re-growth and myogenic precursor cell expansion early after immobility-induced atrophy in human skeletal muscle. J Physiol 2013; 591:3789-804. [PMID: 23732643 DOI: 10.1113/jphysiol.2013.257121] [Citation(s) in RCA: 118] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Recovery of skeletal muscle mass from immobilisation-induced atrophy is faster in young than older individuals, yet the cellular mechanisms remain unknown. We examined the cellular and molecular regulation of muscle recovery in young and older human subjects subsequent to 2 weeks of immobility-induced muscle atrophy. Retraining consisted of 4 weeks of supervised resistive exercise in 9 older (OM: mean age) 67.3, range 61-74 yrs) and 11 young (YM: mean age 24.4, range 21-30 yrs) males. Measures of myofibre area (MFA), Pax7-positive satellite cells (SCs) associated with type I and type II muscle fibres, as well as gene expression analysis of key growth and transcription factors associated with local skeletal muscle milieu, were performed after 2 weeks immobility (Imm) and following 3 days (+3d) and 4 weeks (+4wks) of retraining. OM demonstrated no detectable gains in MFA (vastus lateralis muscle) and no increases in number of Pax7-positive SCs following 4wks retraining, whereas YM increased their MFA (P < 0.05), number of Pax7-positive cells, and had more Pax7-positive cells per type II fibre than OM at +3d and +4wks (P < 0.05). No age-related differences were observed in mRNA expression of IGF-1Ea, MGF, MyoD1 and HGF with retraining, whereas myostatin expression levels were more down-regulated in YM compared to OM at +3d (P < 0.05). In conclusion, the diminished muscle re-growth after immobilisation in elderly humans was associated with a lesser response in satellite cell proliferation in combination with an age-specific regulation of myostatin. In contrast, expression of local growth factors did not seem to explain the age-related difference in muscle mass recovery.
Collapse
Affiliation(s)
- C Suetta
- Institute of Sports Medicine and Center of Healthy Ageing, Faculty of Health and Medical Sciences, University of Copenhagen, Bispebjerg Hospital, Denmark.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Schmidt-Petersen L, Jensen L, Dinsen-Andersen C. DSL-021 Risk Analysis of Medicines Produced in Hospital Pharmacy – a Tool For Ensuring Optimal Supply. Eur J Hosp Pharm 2013. [DOI: 10.1136/ejhpharm-2013-000276.264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
50
|
Savard L, Jensen L, Welsh R. N026 Evaluation of a Nurse Practitioner Telehealth Cardiac Consultation. Can J Cardiol 2012. [DOI: 10.1016/j.cjca.2012.07.772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|